Modified mini-hepcidin peptides and methods of using thereof

ABSTRACT

Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/363,012, filed 5 Jun. 2014, which is a 371 National Phase Entry of PCT/US2012/068180, filed 6 Dec. 2012, and claims the benefit of U.S. Patent Application Ser. No. 61/568,724, filed 9 Dec. 2011, which are herein incorporated by reference in their entirety.

This application is related to U.S. patent application Ser. No. 13/131,792, which is a 371 National Phase entry of PCT/US2009/066711, filed 4 Dec. 2009, and U.S. Provisional Application Ser. No. 61/120,277, filed 5 Dec. 2008, all of which are herein incorporated by reference in their entirety.

ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT

This invention was made with Government support under DK090554, awarded by the National Institutes of Health. The Government has certain rights in the invention.

REFERENCE TO A SEQUENCE LISTING SUBMITTED VIA EFS-WEB

The content of the ASCII text file of the sequence listing named “20151228_034044_097US1_subseq_ST25” which is 42.8 kb in size was created on Dec. 28, 2015, and electronically submitted via EFS-Web on Apr. 6, 2016, is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention generally relates to peptides which exhibit hepcidin activity.

2. Description of the Related Art

Hepcidin, a peptide hormone produced by the liver, is a regulator of iron homeostasis in humans and other mammals. Hepcidin acts by binding to its receptor, the iron export channel ferroportin, and causing its internalization and degradation. Human hepcidin is a 25-amino acid peptide (Hep25). See Krause et al. (2000) FEBS Lett 480:147-150, and Park et al. (2001) J Biol Chem 276:7806-7810. The structure of the bioactive 25-amino acid form of hepcidin is a simple hairpin with 8 cysteines that form 4 disulfide bonds as described by Jordan et al. (2009) J Biol Chem 284:24155-67. The N terminal region is required for iron-regulatory function, and deletion of 5 N-terminal amino acid residues results in a loss of iron-regulatory function. See Nemeth et al. (2006) Blood 107:328-33.

Abnormal hepcidin activity is associated with iron overload diseases which include hereditary hemochromatosis and iron-loading anemias and myelodysplasia. Hereditary hemochromatosis (HH) is a genetic iron overload disease that is mainly caused by hepcidin deficiency, or very rarely by hepcidin resistance. This allows excessive absorption of iron from the diet and development of iron overload. Clinical manifestations of HH may include liver disease (hepatic cirrhosis, hepatocellular carcinoma), diabetes, and heart failure. Currently, the only treatment for HH is regular phlebotomy, which is effective but very burdensome for the patients.

Iron-loading anemias are hereditary anemias with ineffective erythropoiesis such as β-thalassemia, which are accompanied by severe iron overload. Complications from iron overload are the main cause of morbidity and mortality for these patients. Hepcidin deficiency is the main cause of iron overload in untransfused patients, and contributes to iron overload in transfused patients. The current treatment for iron overload in these patients is iron chelation which is very burdensome, sometimes ineffective and accompanied by frequent side effects.

SUMMARY OF THE INVENTION

The present invention generally relates to peptides which exhibit hepcidin activity and methods of using thereof.

The present invention provides peptides, which may be isolated and/or purified, comprising, consisting essentially or consisting of the following Structural Formula IA or IB: A1-A2-A3-A4-A5-A6-A7-A8-A9-A10  IA A10-A9-A8-A7-A6-A5-A4-A3-A2-A1  IB wherein

-   A1 is Asp, D-Asp, Glu, D-Glu, pyroglutamate, D-pyroglutamate, Gln,     D-Gln, Asn, D-Asn, or an unnatural amino acid commonly used as a     substitute thereof such as bhAsp, Ida, Ida(NHPal), and N-MeAsp,     preferably Ida and N-MeAsp; -   A2 is Thr, D-Thr, Ser, D-Ser, Val, D-Val, Ile, D-Ile, Ala, D-Ala or     an unnatural amino acid commonly used as a substitute thereof such     as Tle, Inp, Chg, bhThr, and N-MeThr; -   A3 is His, D-His, Asn, D-Asn, Arg, D-Arg, or an unnatural amino acid     commonly used as a substitute thereof such as L-His(π-Me),     D-His(π-Me), L-His(τ-Me), or D-His(τ-Me); -   A4 is Phe, D-Phe, Leu, D-Leu, Ile, D-Ile, Trp, D-Trp, Tyr, D-Tyr, or     an unnatural amino acid commonly used as a substitute thereof such     as Phg, bhPhe, Dpa, Bip, 1Nal, 2Nal, bhDpa, Amc, PheF5, hPhe, Igl,     or cyclohexylalanine, preferably Dpa; -   A5 is Pro, D-Pro, Ser, D-Ser, or an unnatural amino acid commonly     used as a substitute thereof such as Oic, bhPro, trans-4-PhPro,     cis-4-PhPro, cis-5-PhPro, and Idc, preferably bhPro; -   A6 is Arg, D-Arg, Ile, D-Ile, Leu, D-Leu, Thr, D-Thr, Lys, D-Lys,     Val, D-Val, or an unnatural amino acid commonly used as a substitute     thereof such as D-Nω,ω-dimethyl-arginine, L-Nω,ω-dimethyl-arginine,     D-homoarginine, L-homoarginine, D-norarginine, L-norarginine,     citrulline, a modified Arg wherein the guanidinium group is modified     or substituted, Norleucine, norvaline, bhIle, Ach, N-MeArg, and     N-MeIle, preferably Arg; -   A7 is Cys, D-Cys, Ser, D-Ser, Ala, D-Ala, or an unnatural amino acid     such as Cys(S-tBut), homoCys, Pen, (D)Pen, preferably S-tertiary     butyl-cysteine, Cys(S-S-Pal), Cys(S-S-cysteamine-Pal),     Cys(S-S-Cys-NHPal), and Cys(S-S-Cys); -   A8 is Arg, D-Arg, Ile, D-Ile, Leu, D-Leu, Thr, D-Thr, Lys, D-Lys,     Val, D-Val, or an unnatural amino acid commonly used as a substitute     thereof such as D-Nω,ω-dimethyl-arginine, L-Nω,ω-dimethyl-arginine,     D-homoarginine, L-homoarginine, D-norarginine, L-norarginine,     citrulline, a modified Arg wherein the guanidinium group is modified     or substituted, Norleucine, norvaline, bhIle, Ach, N-MeArg, and     N-MeIle, preferably Arg; -   A9 is Phe, D-Phe, Leu, D-Leu, Ile, D-Ile, Tyr, D-Tyr, Trp, D-Trp,     Phe-R^(a), D-Phe-R^(a), Dpa-R^(a), D-Dpa-R^(a), Trp-R^(a),     bhPhe-R^(a), or an unnatural amino acid commonly used as a     substitute thereof such as PheF5, N-MePhe, benzylamide,     2-aminoindane, bhPhe, Dpa, Bip, 1Nal, 2Nal, bhDpa, and     cyclohexylalanine, which may or may not have R^(a) linked thereto,     preferably bhPhe and bhPhe-R^(a), wherein R^(a) is palmitoyl-PEG-,     wherein PEG is PEG11 or miniPEG3, palmitoyl-PEG-PEG, wherein PEG is     PEG11 or miniPEG3, butanoyl (C4)-PEG11-, octanoyl (C8,     Caprylic)-PEG11-, palmitoyl (C16)-PEG11-, or tetracosanoyl (C24,     Lignoceric)-PEG11-; and -   A10 is Cys, D-Cys, Ser, D-Ser, Ala, D-Ala, or an unnatural amino     acid such as Ida, Ida(NHPal)Ahx, and Ida(NBzl2)Ahx;     wherein the carboxy-terminal amino acid is in amide or carboxy-form;     wherein at least one sulfhydryl amino acid is present as one of the     amino acids in the sequence; and wherein A1, A1 to A2, A10, or a     combination thereof are optionally absent, with the proviso that the     peptide is not one of the peptides as set forth in Table 1. In some     embodiments, the peptides of the present invention contain at least     one of the following: a) A1=N-MeAsp, Ida, or Ida(NHPal); b)     A5=bhPro; c) A6=D-Val, D-Leu, Lys, D-Lys, Arg, D-Arg, Ach, bhArg, or     N-MeArg; d) A7=Cys(S-S-Pal), Cys(S-S-cysteamine-Pal),     Cys(S-S-Cys-NHPal), or Cys(S-S-Cys); and/or e) A8=D-Val, D-Leu, Lys,     D-Lys, Arg, D-Arg, Ach, bhArg, or N-MeArg. In some embodiments, i)     when A1 is Ida and A9 is Phe, then A10 is not Ahx-Ida(NHPal); ii)     when A1 is Ida, A9 is not bhPhe-R^(b), wherein R^(b) is     S-(palmityl)thioglycolic-PEG-; iii) when A4 is D-Phe, A7 is not     D-Cys(S-S-tBut) and A9 is not D-Trp-R^(c), wherein R^(c) is     Butanoyl-PEG11-, Octanoyl-PEG11-, Palmitoyl-PEG11-, or     Tetracosanoyl-PEG11-; or iv) when A1 is Ida and A9 is bhPhe-R^(d),     wherein R^(d) is palmitoyl-PEG-miniPEG3-, A6 and A8 are not both     D-Arg or both bhArg. In some embodiments, A1 is D-Asp, N-MeAsp, Ida,     or Ida(NHPal); A2 is Thr or D-Thr; A3 is His or D-His; A4 is Dpa or     D-Dpa; A5 is Pro, D-Pro, bhPro, or Oic; A6 is Ile, D-Ile, Arg,     D-Val, D-Leu, Ach, or N-MeArg; A7 is Cys, D-Cys, Cys(S-S-Pal),     Cys(S-S-cysteamine-Pal), Cys(S-S-Cys-NHPal), or Cys(S-S-Cys); A8 is     Ile, D-Ile, Arg, D-Val, D-Leu, Ach, or N-MeArg; A9 is Phe, D-Phe,     Dpa, D-Dpa, Trp, D-Trp, bhPhe, Phe-R^(a), D-Phe-R^(a), Dpa-R^(a),     D-Dpa-R^(a), Trp-R^(a), bhPhe-R^(a), wherein R^(a) is     palmitoyl-PEG-, wherein PEG is PEG11 or miniPEG3, palmitoyl-PEG-PEG,     wherein PEG is PEG11 or miniPEG3, butanoyl (C4)-PEG11-, octanoyl     (C8, Caprylic)-PEG11-, palmitoyl (C16)-PEG11-, or tetracosanoyl     (C24, Lignoceric)-PEG11-; and A10, if present, is Ida(NHPal)Ahx or     Ida(NBzl2)Ahx. In some embodiments, A6 and/or A8 is a lysine     derivative such as N-ε-Dinitrophenyl-lysine, N-ε-Methyl-lysine,     N,N-ε-Dimethyl-lysine, and N,N,N-ε-Trimethyl-lysine. In some     embodiments, the peptide is selected from the group consisting of:     PR42′, PR47, PR48, PR49, PR50, PR51, PR52, PR53, PR56, PR57, PR58,     PR59, PR60, PR61, PR63, PR65, PR66, PR67, PR68, PR69, PR70, PR71,     PR72, PR73, PR74, and PR82.

In some embodiments, the peptides form a cyclic structure by a disulfide bond. In some embodiments, the peptides exhibit hepcidin activity. In some embodiments, the peptides bind ferroportin, preferably human ferroportin.

In some embodiments, the present invention provides compositions and medicaments which comprise at least one peptide, which may be isolated, synthesized and/or purified, comprising, consisting essentially or consisting of Structural Formula IA or IB as set forth herein. In some embodiments, the present invention provides method of manufacturing medicaments for the treatment of diseases of iron metabolism, such as iron overload diseases, which comprise at least one peptide, which may be isolated and/or purified, comprising, consisting essentially or consisting of Structural Formula IA or IB as set forth herein. Also provided are methods of treating a disease of iron metabolism in a subject, such as a mammalian subject, preferably a human subject, which comprises administering at least one peptide, which may be isolated and/or purified, comprising, consisting essentially or consisting of Structural Formula IA or IB as set forth herein or a composition comprising said at least one peptide to the subject. In some embodiments, the peptide is administered in a therapeutically effective amount. In some embodiments, the therapeutically effective amount is an effective daily dose administered as a single daily dose or as divided daily doses. The peptides of the present invention can also be administered at a variety of doses.

In some embodiments the dose is given as a weekly dose, e.g. from 1-10,000 μg/kg/dose. In some embodiments, the daily dose is about 1-1,000, preferably about 10-500 μm/kg/day. Dosages can vary according to the type of formulation of peptidyl drug administered as well as the route of administration. One skilled in the art can adjust the dosage by changing the route of administration or formulation, so that the dosage administered would result in a similar pharmacokinetic or biological profile as would result from the preferred dosage ranges described herein. In some embodiments, the composition to be administered is formulated for oral, pulmonary or mucosal administration.

Some embodiments include any dosage with any route of administration which results in an effective pharmacokinetic and pharmacodynamic profile by reducing serum iron values by 10-80%. Some preferred doses include those that result in a desired reduction in serum iron. Administration of the peptidyl or protein formulations of the present invention includes both direct administration, including self-administration, and indirect administration, including the act of prescribing a drug. For example, a physician who instructs a patient to self-administer a drug and/or provides a patient with a prescription for a drug is considered to be administering the drug to the patient.

In some embodiments, the present invention provides methods of binding a ferroportin or inducing ferroportin internalization and degradation which comprises contacting the ferroportin with at least one peptide or composition as disclosed herein.

In some embodiments, the present invention provides kits comprising at least one peptide or composition as disclosed herein packaged together with a reagent, a device, instructional material, or a combination thereof.

In some embodiments, the present invention provides complexes which comprise at least one peptide as disclosed herein bound to a ferroportin, preferably a human ferroportin, or an antibody, such as an antibody which specifically binds a peptide as disclosed herein, Hep25, or a combination thereof.

In some embodiments, the present invention provides the use of at least one peptide, which may be isolated and/or purified, comprising, consisting essentially or consisting of Structural Formula IA or IB as set forth herein or a composition comprising, consisting essentially of, or consisting of said at least one peptide for the manufacture of a medicament for treating a disease of iron metabolism and/or lowering the amount of iron in a subject in need thereof, wherein the medicament is prepared to be administered at an effective daily dose, as a single daily dose, or as divided daily doses. In some embodiments, the dose is about 1-1,000, preferably about 10-500 μm/kg/day. In some embodiments, the medicament is formulated for subcutaneous injection or oral, pulmonary or mucosal administration.

Both the foregoing general description and the following detailed description are exemplary and explanatory only and are intended to provide further explanation of the invention as claimed. The accompanying drawings are included to provide a further understanding of the invention and are incorporated in and constitute part of this specification, illustrate several embodiments of the invention, and together with the description serve to explain the principles of the invention.

DESCRIPTION OF THE DRAWINGS

This invention is further understood by reference to the drawings wherein:

FIG. 1 is a graph showing the relative hepcidin activity of alanine substitutions in Hep25.

FIG. 2A is a graph showing the relative hepcidin activities of F4 substitutions in Hep25.

FIG. 2B is a graph showing the relative hepcidin activities of F9 substitutions in Hep25.

FIG. 3A is a graph showing the hepcidin activities of Hep1-9 and Hep1-10 C7A relative to Hep25 (A).

FIG. 3B is a graph showing the hepcidin activities of Hep1-7 and Hep1-8 relative to Hep1-9 or Hep25.

FIG. 3C is a graph showing the hepcidin activities of Hep4-7, Hep3-7, Hep3-8 and Hep3-9 relative to Hep25.

FIG. 4 is a graph showing the hepcidin activities of C7 modified peptides relative to Hep25 and Hep 1-9.

FIG. 5 is a graph showing in vivo effect (as measured by serum iron levels in mice) of mini-hepcidins Hep1-9, PR6 and PR12 compared to Hep25 or control (PBS). The peptides were injected intraperitoneally, 50 μg peptide per mouse.

FIG. 6 is a graph showing in vivo effect (as measured by serum iron levels in mice) of mini-hepcidin PR27 injected intraperitoneally (20 and 200 nmoles). The amount of injected Hep25 was 20 nmoles.

FIG. 7 is a graph showing in vivo effect (as measured by serum iron levels in mice) of mini-hepcidin riHep7ΔDT injected intraperitoneally (20 and 200 nmoles). The amount of injected Hep25 was 20 nmoles.

FIG. 8 is a graph showing in vivo effect (as measured by serum iron levels in mice) of mini-hepcidins PR27 and PR28 which were first mixed with liposomes and injected intraperitoneally (20 nmoles). The amount of injected Hep25 was 20 nmoles.

FIG. 9 is a graph showing in vivo effect (as measured by serum iron levels in mice) of mini-hepcidin PR27 after oral administration by gavage (200 nmoles).

FIGS. 10A-10C show mini-hepcidin PR65 and its activity in wild-type mice. FIG. 10A shows the structural formula of PR65 (SEQ ID NO:86). Ida=iminodiacetic acid, Dpa=diphenylalanine, bhPro=beta-homo proline, bhPhe=beta-homo phenylalanine. FIG. 10B shows the serum iron in wild-type C57BL/6 mice 4 hours after intraperitoneal injection of solvent, native hepcidin or PR65 (n=4-8 in each group). **p=0.01, *p=0.005. FIG. 10C shows the serum iron in wild-type C57BL/6 mice 4 hours after intraperitoneal or subcutaneous injection of 20 nmoles of PR65 (n=4 in each group). *p=0.007, **p=0.04. In FIGS. 10B and 10C the bars represent mean values and error bars standard deviations.

FIGS. 11A and 11B show the hypoferremic effect of PR65 in iron-loaded hepcidin knockout mice. FIG. 11A shows that PR65 induced a dose-dependent decrease in serum iron 24 hours after a subcutaneous injection. Mean values and standard deviations are shown, n=3-5 mice per point. #p=0.005, &p=0.004, *p<0.001. FIG. 11B shows the time course of hypoferremia induced by a subcutaneous injection of 100 nmoles of PR65. Mean and standard deviations are shown, n=4-6 mice per point. #p=0.008, *p<0.001.

FIG. 12 shows the changes in iron distribution in PR65-treated hepcidin knockout mice. Tissue iron was visualized by enhanced Perls stain at 0-48 hours after subcutaneous injection of PR65 (100 nmoles). Representative images are shown. Horizontal bars indicate 400 μm (10×) and 100 μm (40×). Top row: Spleen iron was scant and its distribution did not change appreciably during the 48 hours. Middle row: Iron in the villus stroma was evident in solvent-treated and 1-4 hour PR65-treated mice, indicating active ferroportin-mediated efflux of iron from basolateral membranes of enterocytes. From 12-24 hours, iron was retained in enterocytes consistent with (mini)hepcidin-induced ferroportin degradation. 48 hours after injection iron was no longer retained by enterocytes. Bottom row: As expected, the livers were iron-loaded at baseline and no changes in the pattern of iron staining were seen within 48 hours of PR65 treatment.

FIGS. 13A-13E show that PR65 prevented iron loading in iron-depleted hepcidin knockout mice. All mice were placed on an iron-deficient diet (4 ppm iron) from ages 5-6 weeks until 12 weeks. The “baseline” group (n=7) was examined at 12 weeks of age (white bars). The rest of the mice were fed an iron-loading diet (300 ppm) for 2 more weeks while receiving daily subcutaneous injections of solvent (grey bars, n=6) or PR65 at 20, 50 or 100 nmoles per day (black bars, n=4 per dose). The mice were analyzed 24 hours after the last injection. Compared to solvent, PR65 injections resulted in: FIG. 13A—iron retention in the spleen; FIG. 13B—a dose-dependent decrease in serum iron; FIG. 13C—a corresponding dose-dependent decrease in Hb levels; FIG. 13D—a decrease in heart iron at higher doses; and FIG. 13E—decreased liver iron. Liver iron content in PR65-injected mice did not significantly differ from that in the baseline group of mice, indicating that little to no new iron was absorbed or deposited in the liver during the 2-week treatment. Graphs show means and standard deviations. Student's t-test was used to compare the mean of each condition to that of solvent treatment (p value over bars). In FIG. 13E, mean of each condition was also compared to the baseline (p values at lines over bars).

FIG. 14 shows the cellular distribution of iron after 2 weeks of PR65 injections for the prevention of iron overload. Representative images are shown. Horizontal bars indicate 400 μm (10×) and 100 μm (40×). Iron accumulation was seen in the splenic red pulp of PR65-treated mice but not solvent-treated mice. Similarly, iron accumulation in duodenal enterocytes was seen only in PR65-treated mice. Compared to heart iron staining of solvent-injected mice, there was less iron accumulation in the heart of animals injected with 50 and 100 nmoles of PR65, consistent with the quantitative method in FIG. 4. Liver iron loading in mice treated with 20 and 50 nmoles of PR65 was similar to that of the baseline group and much less than the iron loading in the solvent-treated group. At the highest PR65 dose, liver iron was lower than at baseline indicating that mice were able to mobilize liver iron despite high mini-hepcidin activity.

FIGS. 15A-15E shows that two-week PR65 treatment of iron-loaded hepcidin knockout mice caused modest redistribution of iron. Hepcidin knockout mice were kept on a 300 ppm iron diet for their entire lifespan. Starting at 12 weeks of age, one group of mice was injected subcutaneously with solvent (n=4) and the other with 50 nmoles of PR65 (n=4) daily for 2 weeks. Iron and hematological parameters were measured 24 hours after the last injection. In PR65-treated mice compared to solvent-treated mice: FIG. 15A—spleen iron increased more than 15-fold confirming PR65 activity; FIG. 15B—serum iron concentrations were similar 24 hours after the last injection; FIG. 15C—hemoglobin decreased by 2 g/dL indicating iron restriction to erythropoiesis; FIG. 15D—heart iron tended to decrease, though the difference was not statistically significant at the number of mice tested; FIG. 15E—liver iron decreased by about 20%.

FIG. 16 shows the cellular distribution of iron after 2 weeks of PR65 injections for the treatment of established iron overload. Tissue sections correspond to the animals analyzed in FIGS. 15A-15E, with representative images shown. Horizontal bars indicate 400 μm (10×) and 100 μm (40×). Enhanced Perls stain confirmed that splenic macrophages and duodenal enterocytes retained iron in PR65-treated but not in solvent-treated mice. Compared to solvent-treated controls, less intense iron staining was observed in the liver of mice treated with PR65. No consistent differences between solvent- and PR65-treated mice were seen in sections of the heart (not shown).

FIG. 17 shows some of the structures of the molecules recited in Tables 1, 3 and 4.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides peptides which are useful in the study and treatment of diseases of iron metabolism.

As used herein, a “disease of iron metabolism” includes diseases where aberrant iron metabolism directly causes the disease, or where iron blood levels are dysregulated causing disease, or where iron dysregulation is a consequence of another disease, or where diseases can be treated by modulating iron levels, and the like. More specifically, a disease of iron metabolism according to this disclosure includes iron overload diseases, iron deficiency disorders, disorders of iron biodistribution, other disorders of iron metabolism and other disorders potentially related to iron metabolism, etc. Diseases of iron metabolism include hemochromatosis, HFE mutation hemochromatosis, ferroportin mutation hemochromatosis, transferrin receptor 2 mutation hemochromatosis, hemojuvelin mutation hemochromatosis, hepcidin mutation hemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis, hepcidin deficiency, transfusional iron overload, thalassemia, thalassemia intermedia, alpha thalassemia, sideroblastic anemia, porphyria, porphyria cutanea tarda, African iron overload, hyperferritinemia, ceruloplasmin deficiency, atransferrinemia, congenital dyserythropoietic anemia, anemia of chronic disease, anemia of inflammation, anemia of infection, hypochromic microcytic anemia, iron-deficiency anemia, iron-refractory iron deficiency anemia, anemia of chronic kidney disease, erythropoietin resistance, iron deficiency of obesity, other anemias, benign or malignant tumors that overproduce hepcidin or induce its overproduction, conditions with hepcidin excess, Friedreich ataxia, gracile syndrome, Hallervorden-Spatz disease, Wilson's disease, pulmonary hemosiderosis, hepatocellular carcinoma, cancer, hepatitis, cirrhosis of liver, pica, chronic renal failure, insulin resistance, diabetes, atherosclerosis, neurodegenerative disorders, multiple sclerosis, Parkinson's disease, Huntington's disease, and Alzheimer's disease. As used herein, “iron overload diseases” and “diseases of iron overload” refer diseases and disorders that result in or may cause abnormally high levels of iron in afflicted subjects if untreated.

In some cases the diseases and disorders included in the definition of “disease of iron metabolism” are not typically identified as being iron related. For example, hepcidin is highly expressed in the murine pancreas suggesting that diabetes (Type I or Type II), insulin resistance, glucose intolerance and other disorders may be ameliorated by treating underlying iron metabolism disorders. See Ilyin, G. et al. (2003) FEBS Lett. 542 22-26, which is herein incorporated by reference. As such, these diseases are encompassed under the broad definition. Those skilled in the art are readily able to determine whether a given disease is a “disease or iron metabolism” according to the present invention using methods known in the art, including the assays of WO 2004092405, which is herein incorporated by reference, and assays which monitor hepcidin, hemojuvelin, or iron levels and expression, which are known in the art such as those described in U.S. Pat. No. 7,534,764, which is herein incorporated by reference.

In preferred embodiments of the present invention, the diseases of iron metabolism are iron overload diseases, which include hereditary hemochromatosis, iron-loading anemias, alcoholic liver diseases and chronic hepatitis C.

As used herein, the terms “protein”, “polypeptide” and “peptide” are used interchangeably to refer to two or more amino acids linked together. Except for the abbreviations for the uncommon or unnatural amino acids set forth in Table 2 below, the three-letter and one-letter abbreviations, as used in the art, are used herein to represent amino acid residues. Except when preceded with “D-”, the amino acid is an L-amino acid. Groups or strings of amino acid abbreviations are used to represent peptides. Except when specifically indicated, peptides are indicated with the N-terminus on the left and the sequence is written from the N-terminus to the C-terminus.

The peptides of the present invention may be made using methods known in the art including chemical synthesis (solid-phase, solution phase, or a combination of both), biosynthesis or in vitro synthesis using recombinant DNA methods. See e.g. Kelly & Winkler (1990) Genetic Engineering Principles and Methods, vol. 12, J. K. Setlow ed., Plenum Press, NY, pp. 1-19; Merrifield (1964) J Amer Chem Soc 85:2149; Houghten (1985) PNAS USA 82:5131-5135; and Stewart & Young (1984) Solid Phase Peptide Synthesis, 2ed. Pierce, Rockford, Ill., which are herein incorporated by reference. The peptides of the present invention may be purified using protein purification techniques known in the art such as reverse phase high-performance liquid chromatography (HPLC), ion-exchange or immunoaffinity chromatography, precipitation, filtration, size exclusion, or electrophoresis. See Olsnes, S. and A. Pihl (1973) Biochem. 12(16):3121-3126; and Scopes (1982) Protein Purification, Springer-Verlag, NY, which are herein incorporated by reference. Alternatively, the peptides of the present invention may be made by recombinant DNA techniques known in the art. Thus, polynucleotides that encode the polypeptides of the present invention are contemplated herein. In preferred embodiments, the polynucleotides are isolated. As used herein “isolated polynucleotides” refers to polynucleotides that are in an environment different from that in which the polynucleotide naturally occurs.

In some embodiments, the peptides of the present invention are substantially purified. As used herein, a “substantially purified” compound refers to a compound that is removed from its natural environment and is at least about 60% free, preferably about 75% free, and most preferably about 90% free from other macromolecular components with which the compound is naturally associated, or a compound that is at least about 60% free, preferably about 75% free, and most preferably about 90% free from other peptide components as measured by HPLC with detection at 214 nm.

As used herein, an “isolated” compound refers to a compound which is isolated from its native environment. For example, an isolated peptide is one which does not have its native amino acids, which correspond to the full length polypeptide, flanking the N-terminus, C-terminus, or both. For example, isolated Hep1-9 refers to an isolated peptide comprising amino acid residues 1-9 of Hep25 which may have non-native amino acids at its N-terminus, C-terminus, or both, but does not have a cysteine amino acid residue following its 9^(th) amino acid residue at the C-terminus. As set forth herein, references to amino acid positions correspond to the amino acid residues of Hep25. For example, reference to amino acid position 9, corresponds to the 9^(th) amino acid residue of Hep25.

The peptides of the present invention bind ferroportin, preferably human ferroportin. Preferred peptides of the present invention specifically bind human ferroportin. As used herein, “specifically binds” refers to a specific binding agent's preferential interaction with a given ligand over other agents in a sample. For example, a specific binding agent that specifically binds a given ligand, binds the given ligand, under suitable conditions, in an amount or a degree that is observable over that of any nonspecific interaction with other components in the sample. Suitable conditions are those that allow interaction between a given specific binding agent and a given ligand. These conditions include pH, temperature, concentration, solvent, time of incubation, and the like, and may differ among given specific binding agent and ligand pairs, but may be readily determined by those skilled in the art.

The peptides of the present invention that mimic the hepcidin activity of Hep25, the bioactive human 25-amino acid form, are herein referred to as “mini-hepcidins”. As used herein, a compound having “hepcidin activity” means that the compound has the ability to lower plasma iron concentrations in subjects (e.g. mice or humans), when administered thereto (e.g. parenterally injected or orally administered), in a dose-dependent and time-dependent manner. See e.g. as demonstrated in Rivera et al. (2005), Blood 106:2196-9.

In some embodiments, the peptides of the present invention have in vitro activity as assayed by the ability to cause the internalization and degradation of ferroportin in a ferroportin-expressing cell line as taught in Nemeth et al. (2006) Blood 107:328-33. In vitro activity may be measured by the dose-dependent loss of fluorescence of cells engineered to display ferroportin fused to green fluorescent protein as in Nemeth et al. (2006) Blood 107:328-33. Aliquots of cells are incubated for 24 hours with graded concentrations of a reference preparation of Hep25 or a mini-hepcidin. As provided herein, the EC₅₀ values are provided as the concentration of a given compound (e.g. peptide) that elicits 50% of the maximal loss of fluorescence generated by the reference Hep25 preparation. EC₅₀ of Hep25 preparations in this assay range from 5 to 15 nM and preferred mini-hepcidins have EC₅₀ values in in vitro activity assays of about 1,000 nM or less.

Other methods known in the art for calculating the hepcidin activity and in vitro activity of peptides according to the present invention may be used. For example, the in vitro activity of compounds may be measured by their ability to internalize cellular ferroportin, which is determined by immunohistochemistry or flow cytometry using antibodies which recognizes extracellular epitopes of ferroportin. Alternatively, the in vitro activity of compounds may be measured by their dose-dependent ability to inhibit the efflux of iron from ferroportin-expressing cells that are preloaded with radioisotopes or stable isotopes of iron, as in Nemeth et al. (2006) Blood 107:328-33.

Design of Mini-Hepcidins

Previous studies indicate that the N-terminal segment of Hep25 is important for its hepcidin activity and is likely to form the contact interface with ferroportin. However, the importance of each N-terminal amino acid to hepcidin activity was unknown. Therefore, alanine-scanning mutagenesis was performed on residues 1-6 of Hep25 to determine the contribution of each N-terminal amino acid to hepcidin activity. As shown in FIG. 1, the T2A substitution did not substantially impact hepcidin activity. Phenylalanine substitutions (F4A or F9A) caused the largest decrease, more than about 70%, in hepcidin activity. The remaining alanine substitutions had detectable decreases in hepcidin activity which were not as significant as the F4A or F9A substitutions.

To determine whether the highly conserved and apparently structurally important F4 phenylalanine is important for hepcidin activity, the F4 amino acid of Hep25 was systematically substituted with other amino acids. As shown in FIG. 2A, making the side-chain more polar (F4Y) led to substantial loss of hepcidin activity as did the substitution with D-phenylalanine (f) or charged amino acids (D, K and Y). However, hepcidin activity was maintained when the F4 residue was substituted with nonaromatic cyclohexylalanine, thereby indicating that a bulky hydrophobic residue is sufficient for activity.

To determine whether the highly conserved and apparently structurally important F9 phenylalanine is important for hepcidin activity, the F9 amino acid of Hep25 was substituted with other amino acids. As shown in FIG. 2B, hepcidin activity not only decreased when F9 was substituted with alanine, but also when it was substituted with nonaromatic cyclohexylalanine, thereby indicating that an aromatic residue may be important for activity.

Mutational studies indicate that C326, the cysteine residue at position 326 of human ferroportin, is the critical residue involved in binding hepcidin. Thus, various N-terminal fragments of Hep25 containing a thiol, i.e. Hep 4-7, Hep3-7, Hep3-8, Hep3-9, Hep1-7, Hep1-8, Hep1-9, and Hep1-10 C7A, were chemically synthesized, refolded and their activities relative to Hep25 were assayed using flow-cytometric quantitation of the ferroportin-GFP degradation, iron efflux estimation based on measurements of cellular ferritin, and radioisotopic iron efflux studies. The sequences and EC₅₀'s of these N-terminal fragments are shown in Table 1.

Remarkably and unexpectedly, as shown in FIG. 3, Hep1-9 and Hep1-10 C7A were found to be quite active in the flow-cytometry assay of ferroportin-GFP internalization. On a mass basis, Hep1-9 and Hep1-10 C7A were only about 4-times less potent and on a molar basis, about 10-times less potent than Hep25. Thus, Hep1-9 and Hep1-10 C7A were used as the basis to construct other peptides having hepcidin activity.

To determine the importance of the cysteine thiol on the hepcidin activity of Hep1-9, the C7 residue of Hep1-9 was substituted with amino acids that have a similar shape but cannot form disulfide bonds to give Hep9-C7S (serine substitution) and Hep9C7-tBut (t-butyl-blocked cysteine) or with a cysteine modified by disulfide coupled tertiary butyl, which can participate in disulfide exchange with HS-t-butyl as the leaving group, to give Hep9C7-SStBut. As shown in FIG. 4, amino acid substitutions that ablated the potential for disulfide formation or exchange caused a complete loss of hepcidin activity, thereby indicating that disulfide formation is required for activity. Other C7 amino acid substitutions and their resulting hepcidin activities are shown in Table 1.

Other peptides based on Hep1-9 and Hep1-10 C7A were constructed to be disulfide cyclized, have unnatural amino acid substitutions, be retroinverted, have modified F4 and F9 residues, or have a positive charge. The C-terminal amino acid was the amidated form. The modifications and the resulting hepcidin activities are shown in Table 1.

As shown in Table 1, with the exception of PR40 and PR41, mini-hepcidins which exhibit EC₅₀'s of about 1000 nM or less contain at least 6 contiguous amino acid residues which correspond to residues 3-8 of Hep25 (see Hep3-8). Thus, in some embodiments, preferred mini-hepcidins have at least 6 contiguous amino acid residues that correspond to 6 contiguous amino acid residues of Hep1-9, preferably residues 3-8. The amino acid residues may be unnatural or uncommon amino acids, L- or D-amino acid residues, modified residues, or a combination thereof.

In some embodiments, the mini-hepcidins of the present invention have at least one amino acid substitution, a modification, or an addition. Examples of amino acid substitutions include substituting an L-amino acid residue for its corresponding D-amino acid residue, substituting a Cys for homoCys, Pen, (D)Pen, Inp, or the like, substituting Phe for bhPhe, Dpa, bhDpa, Bip, 1Nal, and the like. The names and the structures of the substituting residues are exemplified in Table 2. Other suitable substitutions are exemplified in Table 1. Examples of a modification include modifying one or more amino acid residues such that the peptide forms a cyclic structure, retroinversion, and modifying a residue to be capable of forming a disulfide bond. Examples of an addition include adding at least one amino acid residue or at least one compound to either the N-terminus, the C-terminus, or both such as that exemplified in Table 1.

As shown in Table 1, a majority of the mini-hepcidins which exhibit EC₅₀'s of about 100 nM or less contain at least one Dpa or bhDpa amino acid substitution. Thus, in some embodiments, the mini-hepcidins of the present invention have at least one Dpa or bhDpa amino acid substitution.

In view of the alanine substitution data of FIG. 1, in some embodiments, the mini-hepcidins of the present invention may have an Ala at amino acid positions other than amino acid position 4 and 9 as long as there is an available thiol for forming a disulfide bond at amino acid position 7. See Hep9F4A and Hep9C-SStBut in Table 1.

In view of the position 4 amino acid substitution data of FIG. 2 and Table 1, the mini-hepcidins of the present invention may have an amino acid substitution at position 4 which does not result in a substantial change of its charge or polarity as compared to that of Hep25, Hep1-9 or Hep1-10 C7A. Preferred amino acid substitutions at position 4 of Hep1-9 or Hep1-10 C7A include Phe, D-Phe, bhPhe, Dpa, bhDpa, Bip, 1Nal, or the like.

The original mini-hepcidins as referenced herein have the following Structural Formula I A1-A2-A3-A4-A5-A6-A7-A8-A9-A10  I wherein

-   -   A1 is Asp, Glu, pyroglutamate, Gln, Asn, or an unnatural amino         acid commonly used as a substitute thereof;     -   A2 is Thr, Ser, Val, Ala, or an unnatural amino acid commonly         used as a substitute thereof;     -   A3 is His, Asn, Arg, or an unnatural amino acid commonly used as         a substitute thereof;     -   A4 is Phe, Leu, Ile, Trp, Tyr, or an unnatural amino acid         commonly used as a substitute thereof which includes         cyclohexylalanine;     -   A5 is Pro, Ser, or an unnatural amino acid commonly used as a         substitute thereof;     -   A6 is Ile, Leu, Val, or an unnatural amino acid commonly used as         a substitute thereof;     -   A7 is Cys, Ser, Ala, or an unnatural amino acid commonly used as         a substitute thereof which includes S-tertiary butyl-cysteine;     -   A8 is Ile, Leu, Thr, Val, Arg, or an unnatural amino acid         commonly used as a substitute thereof;     -   A9 is Phe, Leu, Ile, Tyr, or an unnatural amino acid commonly         used as a substitute thereof which includes cyclohexylalanine;         and     -   A10 is Cys, Ser, Ala, or an unnatural amino acid commonly used         as a substitute thereof;

wherein the carboxy-terminal amino acid is in amide or carboxy-form;

wherein a Cys or another sulfhydryl amino acid is present as one of the amino acids in the sequence; and

wherein A1, A2, A3, A1 to A2, A1 to A3, A10, A9 to A10, A8 to A10, or a combination thereof are optionally absent.

In some embodiments, A1 is Asp; A2 is Thr; A3 is His; A4 is Phe; A5 is Pro; A6 is Ile; A7 is Ala; A8 is Ile; A9 is Phe; and A10 is Cys in amide form; wherein A1 or A1 to A2 are optionally absent.

In some embodiments, A1 is Asp, A2 is Thr, A3 is His, A4 is Phe, A5 is Pro, A6 is Ile, A7 is Cys or an unnatural thiol amino acid, A8 is Ile, A9 is Phe in amide form, and A10 is absent.

In some embodiments, A1 and A2 are absent, A3 is His, A4 is Phe, A5 is Pro, A6 is Ile, A7 is Cys or an unnatural thiol amino acid, A8 is Ile in amide form, and A9 and A10 are absent.

In some embodiments, A1 and A2 are absent, A3 is His, A4 is Phe, A5 is Pro, A6 is Ile, A7 is Cys or an unnatural thiol amino acid in amide form, and A8 to A10 are absent.

In some embodiments, the unnatural amino acid of A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, or a combination thereof is the corresponding D-amino acid. For example, for A1, the unnatural amino acid may be D-Asp, D-Glu, D-Gln, D-Asn, or the like.

In some embodiments, the unnatural amino acid for:

-   -   A1 is D-Asp, D-Glu, D-pyroglutamate, D-Gln, D-Asn, bhAsp, Ida,         or N-MeAsp;     -   A2 is D-Thr, D-Ser, D-Val, Tle, Inp, Chg, bhThr, or N-MeThr;     -   A3 is D-His, D-Asn, D-Arg, Dpa, (D)Dpa, or 2-aminoindan;     -   A4 is D-Phe, D-Leu, D-Ile, D-Trp, Phg, bhPhe, Dpa, Bip, 1Nal,         bhDpa, Amc, PheF5, hPhe, Igl, or cyclohexylalanine;     -   A5 is D-Pro, D-Ser, Oic, bhPro, trans-4-PhPro, cis-4-PhPro,         cis-5-PhPro, Idc;     -   A6 is D-Ile, D-Leu, Phg, Chg, Amc, bhIle, Ach, and N-MeIle;     -   A7 is D-Cys, D-Ser, D-Ala, Cys(S-tBut), homoCys, Pen, (D)Pen,         Dap(AcBr), and Inp;     -   A8 is D-Ile, D-Leu, D-Thr, D-Val, D-Arg, Chg, Dpa, bhIle, Ach,         or N-MeIle;     -   A9 is D-Phe, D-Leu, D-Ile, PheF5, N-MePhe, benzylamide, bhPhe,         Dpa, Bip, 1Nal, bhDpa, cyclohexylalanine; and     -   A10 is D-Cys, D-Ser, D-Ala.

In some embodiments, the amino acid substitution (and addition, if indicated) for:

-   -   A1 is Ala, D-Ala, Cys, D-Cys, Phe, D-Phe, Asp or D-Asp linked to         Cys or D-Cys, Phe or D-Phe linked to a PEG molecule linked to         chenodeoxycholate, ursodeoxycholate, or palmitoyl, or Dpa or         (D)Dpa linked to palmitoyl;     -   A2 is Ala, D-Ala, Cys, D-Cys, Pro, D-Pro, Gly, or D-Gly;     -   A3 is Ala, D-Ala, Cys, D-Cys, Dpa, Asp or D-Asp linked to Dpa or         (D)Dpa;     -   A4 is Ala, D-Ala, Pro, or D-Pro;     -   A5 is Ala, D-Ala, Pro, D-Pro, Arg, D-Arg;     -   A6 is Ala, D-Ala, Phe, D-Phe, Arg, D-Arg, Cys, D-Cys;     -   A7 is His, or D-His;     -   A8 is Cys, or D-Cys; and     -   A9 is Phe or D-Phe linked to RA, Asp, D-Asp, Asp or D-Asp linked         to RB, bhPhe linked to RC, or cysteamide, wherein RA is         —CONH₂—CH₂—CH₂—S, -D-Pro linked to Pro-Lys or Pro-Arg, -bhPro         linked to Pro linked to Pro-Lys or Pro-Arg, -D-Pro linked to         bhPro-Lys or bhPro-Arg, wherein RB is         -PEG11-GYIPEAPRDGQAYVRKDGEWVLLSTFL, -(PEG11)-(GPHyp)10, and         wherein RC is -D-Pro linked to Pro-Lys or Pro-Arg, -D-Pro linked         to bhPro-Lys or bhPro-Arg.

In some embodiments, the mini-hepcidin is a 10-mer sequence wherein A7 is Ala and A10 is Cys.

In some embodiments, the mini-hepcidin forms a cyclic structure by a disulfide bond.

In some embodiments, the mini-hepcidin is a retroinverted peptide such that A1 is the C-terminus and A10 is the N-terminus and the amino acid residues are D-amino acids. In some embodiments, the retroinverted peptide has at least one addition at the N-terminus, C-terminus, or both. In some embodiments, the retroinverted peptide contains at least one L-amino acid.

In some embodiments, the mini-hepcidin has an amino acid substitution at position 4, position 9, or both. In some embodiments, the amino acid substituent is Phg, Phe, D-Phe, bhPhe, Dpa, Bip, 1Nal, Dpa, bhDpa, Amc, or cysteamide.

In some embodiments, the mini-hepcidin has an amino acid substitution at position 7. In some embodiments, the amino acid substituent is Cys(S-tBut), Ala, D-Ala, Ser, D-Ser, homoCys, Pen, (D)Pen, His, D-His, or Inp.

Examples of some original mini-hepcidins are provided in Table 1.

TABLE 1 EC₅₀ 1 2 3 4 5 6 7 8 9 10 (nM) Name Hep25      10 DTHFPICIFCCG CCHRSKCGMCCKT (SEQ ID NO: 1) Hep10wt D T H F P I C I F C (SEQ ID NO: 2) Length Hep4 (Hep4-7) - - - F P I C - - - >10,000 (SEQ ID NO: 3) Hep5 (Hep3-7) - - H F P I C - - - >10,000 (SEQ ID NO: 4) Hep6 (Hep3-8) - - H F P I C I - -    1000 (SEQ ID NO: 5) Hep7ΔDT (Hep3-9) - - H F P I C I F -     700 (SEQ ID NO: 6) Hep7 (Hep1-7) D T H F P I C - - - >10,000 (SEQ ID NO: 7) Hep8 (Hep1-8) D T H F P I C I - -    2000 (SEQ ID NO: 8) Hep9 (Hep1-9) D T H F P I C I F -      76 (SEQ ID NO: 9) Hep10 D T H F P I A I F C     100 (Hep1-10 C7A) (SEQ ID NO: 10) Thiol Modified Hep9F4A D T H A P I C I F -   >3000 (SEQ ID NO: 11) Hep9C7-SStBut D T H A P I C-S-tBut I F -     700 (SEQ ID NO: 12) Hep9C7-tBut D T H A P I C-tBut I F - >10,000 (SEQ ID NO: 13) Hep9-C7A D T H F P I A I F - >10,000 (SEQ ID NO: 14) Hep9-C7S D T H F P I S I F - >10,000 (SEQ ID NO: 15) (D)C D T H F P I C I F -    1000 (SEQ ID NO: 16) homoC D T H F P I homoCys I F -     900 (SEQ ID NO: 17) Pen D T H F P I Pen I F -     700 (SEQ ID NO: 18) (D)Pen D T H F P I (D)Pen I F -    3000 (SEQ ID NO: 19) Dap(AcBr) D T H F P I Dap(AcBr) I F -  >10000 (SEQ ID NO: 20) Disulfide Cyclized Cyc-1 C-D T H F P I C I F -     300 (SEQ ID NO: 21) Cyc-4 D T H F P I C I F-R1 -  >10000 (SEQ ID NO: 22) Cyc-2 - C H F P I C I F -  >10000 (SEQ ID NO: 23) Cyc-3 - - H F P I C I F-R1 -  >10000 (SEQ ID NO: 24) Unnatural AA's PR10 D Tle H Phg Oic Chg C Chg F -   >3000 (SEQ ID NO: 25) PR11 D Tle H P Oic Chg C Chg F -   >3000 (SEQ ID NO: 26) Retroinverted PR12 F I C I P F H T D -     900* (SEQ ID NO: 27) riHep7ΔDT F I C I P F H - - -     150* (SEQ ID NO: 28) Modified Retroinverted PR23 R2-F I C I P F H T D -     100 (SEQ ID NO: 29) PR24 R3-F I C I P F H T D -    1000* (SEQ ID NO: 30) PR25 F I C I P F H T D-R6 -     600 (SEQ ID NO: 31) PR26 F I C I P F H T D-R6 - >10,000 (SEQ ID NO: 32) PR27 R4-F I C I P F H T D -      20* (SEQ ID NO: 33) PR28 R5-F I C I P F H T D -    3000 (SEQ ID NO: 34) Modified F4 and F9 F4bhPhe D T H bhPhe P I C I F -     700 (SEQ ID NO: 35) F4Dpa D T H Dpa P I C I F -      30 (SEQ ID NO: 36) F4Bip D T H Bip P I C I F -     150 (SEQ ID NO: 37) F4 1Nal D T H 1Nal P I C I F -     110 (SEQ ID NO: 38) F4bhDpa D T H bhDpa P I C I F -      80 (SEQ ID NO: 39) F9bhPhe D T H F P I C I bhPhe -     150 (SEQ ID NO: 40) F9Dpa D T H F P I C I Dpa -      70 (SEQ ID NO: 41) F9Bip D T H F P I C I Bip -     150 (SEQ ID NO: 42) F91Nal D T H F P I C I 1Nal -     200 (SEQ ID NO: 43) F9bhDpa D T H F P I C I bhDpa -     100 (SEQ ID NO: 44) PR39 D T H Dpa P I C I Dpa -      35 (SEQ ID NO: 45) PR40 D - Dpa - P I C I F -      70 (SEQ ID NO: 46) PR41 D - Dpa - P I C I Dpa -     300 (SEQ ID NO: 47) PR43 D T H Dpa P R C R Dpa -     200 (SEQ ID NO: 48) PR44 D T H Dpa Oic I C I F -      30 (SEQ ID NO: 49) PR45 D T H Dpa Oic I C I Dpa -     150 (SEQ ID NO: 50) PR46 D T H Dpa P C C C Dpa -      80 (SEQ ID NO: 51) Positive Charge PR13 D T H F P I C I F-R8 -     100 (SEQ ID NO: 52) PR14 D T H F P I C I F-R9 -      90 (SEQ ID NO: 53) PR15 D T H F P I C I F-R10 -     150 (SEQ ID NO: 54) PR16 D T H F P I C I F-R11 -      50 (SEQ ID NO: 55) PR17 D T H F P I C I F-R12 -     300 (SEQ ID NO: 56) PR18 D T H F P I C I F-R13 -    1000 (SEQ ID NO: 57) PR19 D T H F P I C I bhPhe-R8 -     700 (SEQ ID NO: 58) PR20 D T H F P I C I bhPhe-R9 -     200 (SEQ ID NO: 59) PR21 D T H F P I C I bhPhe-R12 -     500 (SEQ ID NO: 60) PR22 D T H F P I C I bhPhe-R13 -     600 (SEQ ID NO: 61) PR-1 C Inp (D)Dpa Amc R Amc Inp Dpa Cysteamide** -    1500 (SEQ ID NO: 62) PR-2 C P (D)Dpa Amc R Amc Inp Dpa Cysteamide** -    2000 (SEQ ID NO: 63) PR-3 C P (D)Dpa Amc R Amc Inp Dpa Cysteamide** -    1000 (SEQ ID NO: 64) PR-4 C G (D)Dpa Amc R Amc Inp Dpa Cysteamide** -    2000 (SEQ ID NO: 65) R1 = -CONH₂-CH₂-CH₂-S R2 = Chenodeoxycholate-(D)Asp-(PEG11)- R3 = Ursodeoxycholate-(D)Asp-(PEG11)- R4 = Palmitoyl-(PEG11)- R5 = (Palmitoyl)₂-Dap-PEG11-, wherein “Dap” = diaminopropionic acid R6 = -(PEG11)-GYIPEAPRDGQAYVRKDGEWVLLSTFL R7 = -(PEG11)-(GPHyp)10, “GPHyp” = Gly-Pro-hydroxyproline R8 = -PPK R9 = -PPR R10 = -bhProPK R11 = -bhProPR R12 = -PbhProK R13 = -PbhProR Underlined residues = D amino acids “-” indicates a covalent bond, e.g. point of attachment to the given peptide Double underlined = residues connected by a disulfide link to form a cyclized structure *active in vivo **oxidized The PEG compound may be PEG11, i.e. O-(2-aminoethyl)-O′(2-carboxyethyl)-undecaethyleneglycol PR12, riHep7ΔDT, PR23, PR24, PR25, PR26, PR27 and PR28 are retroinverted mini-hepcidins and are shown, left to right, from their C-terminus to their N-terminus.

TABLE 2 Uncommon or Unnatural Amino Acids Chg

L-α-cyclohexylglycine Tle

L-tert-leucine bhPhe

β-homophenylalanine Dpa

3,3-diphenyl-L-alanine bhPro

L-β-homoproline Phg

L-phenylglycine 1Nal

(1-naphthyl)-L-alanine bhDpa

(S)-3-Amino-4,4-diphenylbutanoic acid Bip

L-biphenylalanine Pen

L-Penicillamine (D)Pen

D-Penicillamine Cys(tBut)

S-t-butyl-L-cysteine Oic

octahydroindole-2-carboxylic acid Dap(AcBr)

N^(γ)-(bromoacetyl)-L-2,3-diaminopropionic acid homoCys

L-homocysteine Cys(S-tBut)

S-t-Butylthio-L-cysteine Amc

4-(aminomethyl)cyclohexane carboxylic acid Inp

isonipecotic acid bhAsp

Ida

N-MeAsp

N-MeThr

2-Aminoindane

PheF5

hPhe

Igl

trans-4-PhPro

cis-4-PhPro

cis-5-PhPro

Idc

bhIle

Ach

N-Melle

N-MePhe

Benzylamide

(D)Dpa

3,3-diphenyl-D-alanine Ahx

N-MeArg

2Nal

L-His(π-Me)

L-His(τ-Me)

Peptide Synthesis

Hep25 was synthesized at the UCLA Peptide Synthesis Core Facility using solid phase 9-fluorenylmethyloxycarbonyl (fmoc) chemistry. Specifically, the peptides were synthesized on an ABI 431A peptide synthesizer (PE Biosystems, Applied Biosystems, Foster City, Calif.) using fmoc amino acids, Wang resin (AnaSpec, San Jose, Calif.), and double coupling for all residues. After cleavage, 30 mg crude peptides was reduced with 1000-fold molar excess of dithiothreitol (DTT) in 0.5 M Tris buffer (pH 8.2), 6 M guanidine hydrochloride, and 20 mM EDTA at 52° C. for 2 hours. Fresh DTT (500-molar excess) was added and incubated for an additional hour at 52° C. The reduced peptides were purified on the 10-g C18 SEP-PAK cartridges (Waters, Milford, Mass.) equilibrated in 0.1% TFA and eluted with 50% acetonitrile. The eluates were lyophilized and resuspended in 0.1% acetic acid. The reduced peptides were further purified by reversed-phase high-performance liquid chromatography (RP-HPLC) on VYDAC C18 column (218TP510; Waters) equilibrated with 0.1% trifluoroacetic acid and eluted with an acetonitrile gradient. The eluates were lyophilized, dissolved in 0.1% acetic acid, 20% DMSO, to the approximate concentration of 0.1 mg/ml (pH 8), and air oxidized by stirring for 18 hours at room temperature. The refolded peptides were also purified sequentially on the 10-g C18 SEP-PAK cartridge and on the RP-HPLC VYDAC C18 column using an acetonitrile gradient. The eluates were lyophilized and resuspended in 0.016% HCl. The conformation of refolded synthetic hepcidin derivatives was verified by electrophoresis in 12.5% acid-urea polyacrylamide gel electrophoresis (PAGE), and peptide masses were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS; UCLA Mass Spectrometry Facility, Los Angeles, Calif.).

The other peptides set forth in Table 1 were synthesized by the solid phase method using either Symphony® automated peptide synthesizer (Protein Technologies Inc., Tucson, Ariz.) or CEM Liberty automatic microwave peptide synthesizer (CEM Corporation Inc., Matthews, N.C.), applying 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry (Fields & Noble (1990) Int J Pept Protein Res 35:161-214) and commercially available amino acid derivatives and reagents (EMD Biosciences, San Diego, Calif. and Chem-Impex International, Inc., Wood Dale, Ill.). Peptides were cleaved from resin using modified reagent K (TFA 94% (v/v); phenol, 2% (w/v); water, 2% (v/v); TIS, 2% (v/v); 2 hours) and precipitated by addition of ice-cold diethyl ether. Subsequently, peptides were purified by preparative reverse-phase high performance liquid chromatography (RP-HPLC) to >95% homogeneity and their purity evaluated by matrix-assisted laser desorption ionization spectrometry (MALDI-MS, UCLA Mass Spectrometry Facility, Los Angeles, Calif.) as well as analytical RP-HPLC employing Varian ProStar 210 HPLC system equipped with ProStar 325 Dual Wavelength UV-Vis detector with the wavelengths set at 220 nm and 280 nm (Varian Inc., Palo Alto, Calif.). Mobile phases consisted of solvent A, 0.1% TFA in water, and solvent B, 0.1% TFA in acetonitrile. Analyses of peptides were performed with a reversed-phase C18 column (Vydac 218TP54, 4.6×250 mm, Grace, Deerfield, Ill.) applying linear gradient of solvent B from 0 to 100% over 100 min (flow rate: 1 ml/min).

Other methods known in the art may be used to synthesize or obtain the peptides according to the present invention. All peptides were synthesized as carboxyamides (—CONH₂) which creates a charge-neutral end more similar to a peptide bond than the negatively charged —COOH end. Nevertheless, peptides having the negatively charged —COOH end are contemplated herein.

Activity Assays

Flow Cytometry.

The activity of peptides of the present invention was measured by flow cytometry as previously described. See Nemeth et al. (2006) Blood 107:328-333, which is herein incorporated by reference. ECR293/Fpn-GFP, a cell line stably transfected with a ponasterone-inducible ferroportin construct tagged at the C-terminus with green fluorescent protein was used. See Nemeth et al. (2004) Science 306:2090-2093, which is herein incorporated by reference. Briefly, the cells were plated on poly-D-lysine coated plates in the presence of 20 μM FAC, with or without 10 μM ponasterone. After 24 hours, ponasterone was washed off, and cells were treated with peptides for 24 hours. Cells were then trypsinized and resuspended at 1×10⁶ cells/ml, and the intensity of green fluorescence was analyzed by flow cytometry. Flow cytometry was performed on FAC SCAN (fluorescence activated cell scanner) Analytic Flow Cytometer (Becton Dickinson, San Jose, Calif.) with CELLQUEST version 3.3 software (Becton Dickinson). Cells not induced with ponasterone to express Fpn-GFP were used to establish a gate to exclude background fluorescence. Cells induced with ponasterone, but not treated with any peptides, were used as the positive control. Each peptide was tested over the range of concentrations (0, 0.01, 0.03, 0.1, 0.3, 1, 3 and 10 μM). Each peptide treatment was repeated independently 3 to 6 times. For each concentration of peptide, the results were expressed as a fraction of the maximal activity (F_(Hep25)) of Hep25 (in the dose range 0.01-10 μM), according to the formula 1−((F_(x)−F_(Hep25))/(F_(untreated)−F_(Hep25))), where F was the mean of the gated green fluorescence and x was the peptide. The IEC₅₀ concentrations are set forth in the Table 1.

Ferritin Assay.

Cells treated with peptides having hepcidin activity will retain iron and contain higher amounts of ferritin. Thus, following ferritin assay may be used to identify mini-hepcidins according to the present invention. Briefly, HEK293-Fpn cells are incubated with 20 μM FAC with or without 10 μM ponasterone. After 24 hours, ponasterone is washed off, and hepcidin derivatives are added for 24 hours in the presence of 20 μM FAC. Cellular protein is extracted with 150 mM NaCl, 10 mM EDTA, 10 mM Tris (pH 7.4), 1% Triton X-100, and a protease inhibitor cocktail (Sigma-Aldrich, St Louis, Mo.). Ferritin levels are determined by an enzyme-linked immunosorbent assay (ELISA) assay (Ramco Laboratories, Stafford, Tex., or Biotech Diagnostic, Laguna Niguel, Calif.) according to the manufacturer's instructions and are normalized for the total protein concentration in each sample, as determined by the bicinchoninic acid (BCA) assay (Pierce, Rockford, Ill.).

In Vivo Assays. Serum Iron Assay.

The decrease in serum iron after peptide administration is the principal measure of hepcidin activity. Thus, as provided herein, the hepcidin activity of selected peptides of the present invention were assayed in vivo by measuring serum iron in test subjects. Briefly, C57/Bl6J mice were maintained on NIH 31 rodent diet (333 parts per million (ppm) iron; Harlan Teklad, Indianapolis, Ind.). Two weeks before the experiment, the mice were switched to a diet containing about 2-4 ppm iron (Harlan Teklad, Indianapolis, Ind.) in order to suppress endogenous hepcidin. Peptide stocks were diluted to desired concentrations in sterile phosphate buffered saline (PBS) or other diluents as described next. Mice were subjected to the following treatments: (a) Injected intraperitoneally either with 100 μl PBS (control) or with 50 μg peptide in 100 μl PBS; (b) Injected with 100 μl of peptide (or PBS) mixed with 500 μg empty liposomes COATSOME EL series (NOF, Tokyo, Japan) (prepared as per manufacturer's recommendation); (c) Injected with 100 μl peptides (or PBS) solubilized with SL220 solubilization agent (NOF, Tokyo, Japan); (d) Gavaged with 250 μl of peptide (or PBS) in 1× solvent (Cremophor EL (Sigma)/ethanol/PBS; (12.5:12.5:75)). Mice were sacrificed 4 hours later, blood was collected by cardiac puncture, and serum was separated using MICROTAINER tubes (Becton Dickinson, Franklin Lakes, N.J.). Serum iron was determined by using a colorimetric assay (Diagnostic Chemicals, Oxford, Conn.), which was modified for the microplate format so that 10 μl serum was used per measurement. The results were expressed as the percentage of decrease in serum iron when compared with the average value of serum iron levels in PBS-treated mice.

As shown in FIG. 5, intraperitoneal (i.p.) administration of 50 μg PR12 per mouse in PBS caused a significant decrease in serum iron after 4 hours, when compared to i.p. administration of PBS. The serum iron decrease was similar to that caused by i.p. injection of 50 μg of Hep25. Injection (i.p.) of Hep9 did not result in a serum iron decrease. PR12 is a retroinverted form of Hep9, and is resistant to proteolysis because of the retroinverted structure. The experiment indicates that increased proteolytic resistance improves the activity of mini-hepcidins.

As shown in FIG. 6, i.p. administration of 200 nmoles of riHep7ΔDT in PBS resulted in serum iron concentrations significantly lower than those achieved after injection of PBS, and also lower than i.p. injection of 20 nmoles of Hep25. Administration of 20 nmoles of riHep7ΔDT slightly but not significantly reduced serum iron concentrations. The experiment indicates that after i.p. injection peptides as small as 7 amino acids are able to display activity comparable to Hep25.

As shown in FIG. 7, i.p. administration of 20 nmoles PR27 in PBS caused a serum iron decrease comparable to that caused by i.p. administration of 20 nmoles Hep25. This indicated that mini-hepcidin can achieve similar potency to Hep25 in vivo. Higher concentration of PR27 (200 nmoles) caused even greater decrease in serum iron concentrations.

As shown in FIG. 8, i.p. administration of 20 nmoles PR27 in liposomal solution also caused a serum iron decrease similar to that caused by i.p. administration of 20 nmoles Hep25. Administration of liposomal solution by itself did not affect serum iron levels. The liposomal solution was prepared by mixing 100 μl of PBS with 500 μg empty liposomes COATSOME EL series (NOF, Tokyo, Japan) (prepared as per manufacturer's recommendation). Mini-hepcidin PR28 dissolved in liposomal solution, however, showed lesser ability to decrease serum iron than PR27. The experiment indicates that suspension of peptides in liposomes does not affect their activity. Thus, liposomes may be useful for oral administration of peptides according to the present invention.

As shown in FIG. 9, oral administration of PR27 200 nmoles by gavage in a cremophore EL solution caused a decrease in serum iron in mice as compared to oral administration of PBS in the same formulation. Cremophor EL increases solubility of chemicals, and is frequently used excipient or additive in drugs. Cremophor EL solution was prepared by mixing Cremophor EL (Sigma), ethanol and PBS in a ratio 12.5:12.5:75. 250 μl of the solution was administered by gavage to mice.

Thus, the present invention may be used to decrease serum iron in subjects. A preferred mini-hepcidin according to the present invention is a retroinverted peptide which comprises a PEG molecule, such as PEG11, linked to its N-terminal amino acid. In some embodiments, the PEG molecule is linked to palmitoyl group or diaminopropionic acid linked to one or more palmitoyl groups.

In addition to assaying the effect on serum iron content, other in vivo assays known in the art may be conducted to identify mini-hepcidins according to the present invention and/or determine the therapeutically effective amount of a given peptide or mini-hepcidin according to the present invention. Examples of such assays include the following:

Tissue Iron Assay.

In addition to or instead of the serum iron assay above, tissue iron distribution can be determined by enhanced Perl's stain of liver and spleen sections obtained from the treated mice. Briefly, the tissue sections are fixed in 4% paraformaldehyde/PBS, incubated in Perl's solution (1:1, 2% HCl and 2% potassium ferrocyanide) and diaminobenzidine in 0.015% hydrogen peroxide. Tissue non-heme iron may be quantitated using the micromethod of Rebouche et al. (2004) J Biochem Biophys Methods. 58(3):239-51; Pak et al. (2006) Blood 108(12):3730-5. 100 mg pieces of liver and spleen are homogenized and acid is added to release non-heme bound iron which is detected by colorimetric reaction using ferrozine and compared to controls. Treatment with mini-hepcidins would be expected to cause redistribution of iron from other tissues to the spleen. Over weeks to months, the administration of mini-hepcidins would be expected to decrease tissue iron content in all tissues because of diminished dietary iron absorption.

Hematology Assays.

Hematology assays may be used to identify mini-hepcidins according to the present invention and/or determine the therapeutically effective amount of a given peptide or mini-hepcidin according to the present invention. Briefly, blood from treated subjects is collected into heparin-containing tubes. Hemoglobin, RBC, MCV, EPO, white cell parameters, reticulocyte counts, and reticulocyte Hgb content are determined using methods known in the art and compared to controls. Treatment with mini-hepcidins would be expected to cause a decrease in MCV and diminish the Hgb content of reticulocytes. Administration of mini-hepcidins in excessive amounts would be expected to decrease Hgb.

Iron Export Assays.

Iron (⁵⁵Fe) export assays known in the art using primary hepatocytes and macrophages may be used to identify mini-hepcidins according to the present invention and/or determine the therapeutically effective amount of a given peptide or mini-hepcidin according to the present invention. Peptides having hepcidin activity will diminish or decrease the release of ⁵⁵Fe from cells. Briefly, cells are incubated with ⁵⁵Fe-NTA or ⁵⁵Fe-Tf for 36 hours. After washing off unincorporated ⁵⁵Fe, cells are treated with a given peptide or a control. In case of ferroportin mutants, the transfection is performed prior to addition of ⁵⁵Fe and expression allowed to proceed during the 36 hour iron-loading period. Aliquots of the media are collected after 1, 4, 8, 24, 36, 48 and 72 hours and radioactivity is determined by a scintillation counter. Cell-associated radioactivity can be measured by centrifuging cells through silicone oil to lower the non-specific binding of radiolabeled iron to cells using methods known in the art.

To determine whether a given peptide modifies the internalization and degradation of endogenous ferroportin, the protein levels and cellular distribution of ferroportin in hepatocytes and macrophages treated with the peptide may be assayed using Western blotting, immunohistochemistry and ferroportin antibodies known in the art.

Modified Mini-Hepcidins

Additional mini-hepcidins according to the present invention are shown in Table 3 and Table 4 as follows:

TABLE 3 EC₅₀ Active @ (nM) in 20 nmoles/ Name 1 2 3 4 5 6 7 8 9 10 vitro mouse IP Hept10wt D T H F P I C I F C (SEQ ID NO: 2) PR42′ D T H Dpa P R C R Dpa 30 (SEQ ID NO: 67) PR47 D T H Dpa P I C I F-R4 50 N (SEQ ID NO: 68) PR48 D T H Dpa P I C I Dpa-R4 50 N (SEQ ID NO: 69) PR49 H Dpa P I C I F-R4 <10 N (SEQ ID NO: 70) PR50 H Dpa P I C I Dpa-R4 <10 N (SEQ ID NO: 71) PR51 D T H Dpa P V C V F-R4 100 (SEQ ID NO: 72) PR52 D T H Dpa P L C L F-R4 <10 (SEQ ID NO: 73) PR53 N-MeAsp T H Dpa P I C I bhPhe-R14 10 (SEQ ID NO: 74) PR54 N-MeAsp T H Dpa bhPro I C I bhPhe-R14 10 (SEQ ID NO: 75) PR55 N-MeAsp T H Dpa P Ach C Ach F-R14 10 (SEQ ID NO: 76) PR56 N-MeAsp T H Dpa Oic R C R bhPhe-R14 15 (SEQ ID NO: 77) PR57 N-MeAsp T H Dpa bhPro R C R bhPhe-R14 2 Y (SEQ ID NO: 78) PR58 Ida T H Dpa P I C I bhPhe-R14 1 (SEQ ID NO: 79) PR59 Ida T H Dpa bhPro I C I bhPhe-R14 2 N (SEQ ID NO: 80) PR60 Ida T H Dpa P Ach C Ach F-R14 3 Y* (SEQ ID NO: 81) PR61 Ida T H Dpa bhPro R C R bhPhe-R14 10-100 Y (also (SEQ ID NO: 82) by SQ) R4 = Palmitoyl-(PEG11)-, PEG11 = O-(2-aminoethyl)-O′-(2-carboxyethyl)-undecaethyleneglycol R14= Palmitoyl-PEG-miniPEG3-, and “miniPEG3” = 11-amino-3,6,9-trioxaundecanoic acid Underlined residues = D amino acids “—” indicates a covalent bond, e.g. point of attachment to the given peptide IP = intraperitoneal administration, SQ = subcutaneous administration *= Exhibits detectable and reproducible activity at about 50% lower than the most active compounds in Table 3 and 4. As used herein, “Active” means that at 4 hours after injection serum iron in peptide-injected mice decreased statistically significantly (p < 0.05) compared to solvent-injected mice. “Activity” refers to the % decrease of serum iron 4 hours after injection compared to solvent-treated mice. In some embodiments, PEG11 can be substituted with miniPEG3 and miniPEG3 can be substituted with PEG11.

TABLE 4 Active @ 20 nmoles/ mouse Name 1 2 3 4 5 6 7 8 9 10 IP SQ Hep10wt D T H F P I C I F C (SEQ ID NO: 2) PR62 Ida T H Dpa bhPro R C R bhPhe-R14 N (SEQ ID NO: 83) PR63 Ida T H Dpa bhPro N-MeArg C N-MeArg bhPhe-R14 Y (SEQ ID NO: 84) PR64 Ida T H Dpa bhPro bhArg C bhArg bhPhe-R14 N (SEQ ID NO: 85) PR65 Ida T H Dpa bhPro R C R bhPhe-R15 Y Y (SEQ ID NO: 86) PR66 Ida T H Dpa bhPro R C R bhPhe Y N (SEQ ID NO: 87) PR67 Ida T H Dpa bhPro R Cys(S-S- R bhPhe Y Y (SEQ ID NO: 88) Pal) PR68 Ida T H Dpa bhPro R Cys(S-S- R bhPhe Y (SEQ ID NO: 89) cysteamine- Pal) PR69 Ida T H Dpa bhPro R Cys(S-S- R bhPhe Y* (SEQ ID NO: 90) Cys-NHPal) PR70 Ida T H Dpa bhPro R Cys(S-S- R bhPhe-R14 Y* (SEQ ID NO: 91) Cys) PR71 Ida(NHPal) T H Dpa bhPro R C R bhPhe Y* N (SEQ ID NO: 92) PR72 Ida T H Dpa bhPro R C R bhPhe Ida(NHPal) Y N (SEQ ID NO: 93) PR73 Ida T H Dpa bhPro R C R bhPhe Ahx- Y (SEQ ID NO: 94) Ida(NHPal) PR74 Ida T H Dpa bhPro R C R bhPhe Ahx- Y (SEQ ID NO: 95) Ida(NBzI2) PR75 Ida T H Dpa bhPro R C R bhPhe-R16 N (SEQ ID NO: 96) PR76 D T H F P R Cys(S-S- R W-R17 N (SEQ ID NO: 97) tBut) PR77 D T H F P R Cys(S-S- R W-R18 N (SEQ ID NO: 98) tBut) PR78 D T H F P R Cys(S-S- R W-R19 N (SEQ ID NO: 99) tBut) PR79 D T H F P R Cys(S-S- R W-R20 N (SEQ ID NO: 100) tBut) PR82 Ida T H Dpa bhPro R C R W Ahx- Y (SEQ ID NO: 101) Ida(NHPal) R4 = Palmitoyl-(PEG11)-, wherein PEG11 = O-(2-aminoethyl)-O′-(2-carboxyethyl)-undecaethyleneglycol R14 = Palmitoyl-PEG-miniPEG3-, and “miniPEG3” = 11-amino-3,6,9-trioxaundecanoic acid R15 = Palmitoyl-PEG- R16 = S-(Palmityl)thioglycolic-PEG- R17 = Butanoyl-PEG11- R18 = Octanoyl-PEG11- R19 = Palmitoyl-PEG11- R20 = Tetracosanoyl-PEG11- Ahx-Ida(NHPal) = Aminohexanoic acid spacer between peptide residue 9 and Ida residue; Palmitylamine amide on Ida side chain Ida(NHPal) = Palmitylamine amide on Ida side chain Ida(NBzI2) = N,N′-Dibenzylamine amide on Ida side chain Cys(S-S-Pal) = Palmitoyl attached to Cys7 via a disufide bond Cys(S-S-cysteamine-Pal) = Palmitoyl attached to Cys7 via SS-Cysteamine Cys(S-S-Cys-NHPal) = Palmitylamine attached to Cys7 via another Cys Cys(S-S-Cys) = Cys attached to Cys7 via disulfide bond Underlined residues = D amino acids “—” indicates a covalent bond, e.g. point of attachment to the given peptide *= detectable and reproducible activity but at least 50% lower than other active compounds in Table 4. As used herein, “Active” means that the injection of the compound resulted in statistically significant (p < 0.05) lowering of serum iron compared to solvent injection when measured 4 hours after administration. “Activity” refers to the % decrease of serum iron 4 hours after injection compared to solvent-treated mice. IP = intraperitoneal administration, SQ = subcutaneous administration In some embodiments, PEG11 can be substituted with miniPEG3. In some embodiments, miniPEG3 can be substituted with PEG11. In some embodiments, PEG can be substituted with PEG11, but not miniPEG3.

In Tables 3 and 4, PR47, PR48, PR49, PR50, PR51, PR52, PR76, PR77, PR78, and PR79 are retroinverted mini-hepcidins and are shown, left to right, from their C-terminus to their N-terminus in order to exemplify the alignment between their amino acid residues and that of residues 1-10 of Hep25. Thus, the conventional recitation of these retroinverted mini-hepcidins from their N-terminus to their C-terminus are as follows (D amino acids are underlined):

PR47: R4-F-I-C-I-P-Dpa-H-T-D

PR48: R4-Dpa-I-C-I-P-Dpa-H-T-D

PR49: R4-F-I-C-I-P-Dpa-H

PR50: R4-Dpa-I-C-I-P-Dpa-H

PR51: R4-F-V-C-V-P-Dpa-H-T-D

PR52: R4-F-L-C-L-P-Dpa-H-T-D

PR76: R17-W-R-Cys(S-S-tBut)-R-P-F-H-T-D

PR77: R18-W-R-Cys(S-S-tBut)-R-P-F-H-T-D

PR78: R19-W-R-Cys(S-S-tBut)-R-P-F-H-T-D

PR79: R20-W-R-Cys(S-S-tBut)-R-P-F-H-T-D

As shown in Table 4, the route of administration may play a role in the activity of the given mini-hepcidin (compare, for example, PR65 and PR66). Thus, the indication of no activity of some of the mini-hepcidins in Tables 3 and 4 should not be interpreted as indicating that the given mini-hepcidin lacks any activity at any route of administration and/or dosage. In fact, as shown in Table 3, quite a few of such mini-hepcidins exhibit significant in vitro activity at considerably lower dosages as the original mini-hepcidins.

These additional mini-hepcidins are modifications of the mini-hepcidins as set forth in PCT/US2009/066711 (hereinafter referred to as “original mini-hepcidins” and having the Structural Formula I). As used herein, mini-hepcidins which are modifications of the original mini-hepcidins are referred to herein as “modified mini-hepcidins”. As used herein, “mini-hepcidins” refers to both original mini-hepcidins and modified mini-hepcidins. Modified mini-hepcidins according to the present invention have the following Structural Formula IA or IB: A1-A2-A3-A4-A5-A6-A7-A8-A9-A10  IA A10-A9-A8-A7-A6-A5-A4-A3-A2-A1  IB

-   A1 is Asp, D-Asp, Glu, D-Glu, pyroglutamate, D-pyroglutamate, Gln,     D-Gln, Asn, D-Asn, or an unnatural amino acid commonly used as a     substitute thereof such as bhAsp, Ida, Ida(NHPal), and N-MeAsp,     preferably Ida and N-MeAsp; -   A2 is Thr, D-Thr, Ser, D-Ser, Val, D-Val, Ile, D-Ile, Ala, D-Ala or     an unnatural amino acid commonly used as a substitute thereof such     as Tle, Inp, Chg, bhThr, and N-MeThr; -   A3 is His, D-His, Asn, D-Asn, Arg, D-Arg, or an unnatural amino acid     commonly used as a substitute thereof such as L-His(π-Me),     D-His(π-Me), L-His(τ-Me), or D-His(τ-Me); -   A4 is Phe, D-Phe, Leu, D-Leu, Ile, D-Ile, Trp, D-Trp, Tyr, D-Tyr, or     an unnatural amino acid commonly used as a substitute thereof such     as Phg, bhPhe, Dpa, Bip, 1Nal, 2Nal, bhDpa, Amc, PheF5, hPhe, Igl,     or cyclohexylalanine, preferably Dpa; -   A5 is Pro, D-Pro, Ser, D-Ser, or an unnatural amino acid commonly     used as a substitute thereof such as Oic, bhPro, trans-4-PhPro,     cis-4-PhPro, cis-5-PhPro, and Idc, preferably bhPro; -   A6 is Arg, D-Arg, Ile, D-Ile, Leu, D-Leu, Thr, D-Thr, Lys, D-Lys,     Val, D-Val, or an unnatural amino acid commonly used as a substitute     thereof such as D-Nω,ω-dimethyl-arginine, L-Nω,ω-dimethyl-arginine,     D-homoarginine, L-homoarginine, D-norarginine, L-norarginine,     citrulline, a modified Arg wherein the guanidinium group is modified     or substituted, Norleucine, norvaline, bhIle, Ach, N-MeArg, and     N-MeIle, preferably Arg; -   A7 is Cys, D-Cys, Ser, D-Ser, Ala, D-Ala, or an unnatural amino acid     commonly used as a substitute thereof such as Cys(S-tBut), homoCys,     Pen, (D)Pen, preferably S-tertiary butyl-cysteine, Cys(S-S-Pal),     Cys(S-S-cysteamine-Pal), Cys(S-S-Cys-NHPal), and Cys(S-S-Cys) or any     amino acid derivative having an exchangeable cysteine; -   A8 is Arg, D-Arg, Ile, D-Ile, Leu, D-Leu, Thr, D-Thr, Lys, D-Lys,     Val, D-Val, or an unnatural amino acid commonly used as a substitute     thereof such as D-Nω,ω-dimethyl-arginine, L-Nω,ω-dimethyl-arginine,     D-homoarginine, L-homoarginine, D-norarginine, L-norarginine,     citrulline, a modified Arg wherein the guanidinium group is modified     or substituted, Norleucine, norvaline, bhIle, Ach, N-MeArg, and     N-MeIle, preferably Arg; -   A9 is Phe, D-Phe, Leu, D-Leu, Ile, D-Ile, Tyr, D-Tyr, Trp, D-Trp,     Phe-R^(a), D-Phe-R^(a), Dpa-R^(a), D-Dpa-R^(a), Trp-R^(a),     bhPhe-R^(a), or an unnatural amino acid commonly used as a     substitute thereof such as PheF5, N-MePhe, benzylamide,     2-aminoindane, bhPhe, Dpa, Bip, 1Nal, 2Nal, bhDpa, and     cyclohexylalanine, which may or may not have R^(a) linked thereto,     preferably bhPhe and bhPhe-R^(a), wherein R^(a) is palmitoyl-PEG-,     wherein PEG is PEG11 or miniPEG3, palmitoyl-PEG-PEG, wherein PEG is     PEG11 or miniPEG3, butanoyl (C4)-PEG11-, octanoyl (C8,     Caprylic)-PEG11-, palmitoyl (C16)-PEG11-, or tetracosanoyl (C24,     Lignoceric)-PEG11-; and -   A10 is Cys, D-Cys, Ser, D-Ser, Ala, D-Ala, or an unnatural amino     acid such as Ida, Ida(NHPal)Ahx, and Ida(NBzl2)Ahx;     wherein the carboxy-terminal amino acid is in amide or carboxy-form;     wherein at least one sulfhydryl amino acid is present as one of the     amino acids in the sequence (and preferably, the sulfydryl group is     capable of exchange); and     wherein A1, A1 to A2, A10, or a combination thereof are optionally     absent, with the proviso that the peptide is not one of the peptides     as set forth in Table 1. In some embodiments, the modified     mini-hepcidin forms a cyclic structure by a disulfide bond. In some     embodiments, the N-terminal amino acid is a free amine. In some     embodiments, the N-terminal amino acid is a blocked amine such as     with an acetyl group. In some embodiments, A6 and/or A8 is a lysine     derivative such as N-ε-Dinitrophenyl-lysine, N-ε-Methyl-lysine,     N,N-ε-Dimethyl-lysine, and N,N,N-ε-Trimethyl-lysine.

Five of the modified mini-hepcidins in Table 4 contain tryptophan in order to facilitate measurements of their concentration. Thus, in some embodiments, the modified mini-hepcidins of the present invention contain tryptophan. In some embodiments, the tryptophan residue(s) is deleted or substituted with another amino acid. Other modified mini-hepcidins were made by modifying original mini-hepcidins by substituting the two isoleucines flanking the cysteine with arginines or arginine derivatives. Unexpectedly, it was found that substituting these isoleucines with arginines resulted in mini-hepcidins with increased activity. It is believed that the unexpectedly superior activity is the result of the presence of arginine at the 6th amino acid position and/or the 8th amino acid position. Thus, in some embodiments, the amino acid residue at position A6 and/or A8 of structural formula I is arginine. Additional modifications of such mini-hepcidins also resulted in unexpectedly higher activities. The modified mini-hepcidins according to the present invention unexpectedly exhibit superior activity as compared to the modified mini-hepcidins exemplified in U.S. Ser. No. 13/131,792. In addition, it was found that many of the modified mini-hepcidins retain their activity when subcutaneously administered.

In some embodiments the N-terminal amino acid has a free amine. In some embodiment the N-terminal amine is blocked with a group that removes its charge, preferably an acetyl or formal group. In some embodiments the N-terminal amine is modified to be conjugated with an acyl chain with preferred embodiments with a fatty acid such as caprylic, capric, lauric, myristic, palmitic, or stearic such that an acyl chain is on the N-terminus. The acyl chain also may be attached via a linker commonly known in the art, e.g. a polyethylene glycol linker, preferably PEG3.

In some embodiments, the side-chain of amino acid A1 can be modified as indicated for the N-terminal amine. For example, the free carbonyl group on the amino acid A1 can be modified, e.g. blocked by an acyl group such as palmitoyl (see PR71).

In some embodiment, A4 is a bulky hydrophobic amino acid such as Phe, Tyr, Trp, Leu, or Ile or any unnatural amino acid commonly used as a substitute thereof that contains 4 or more carbons in its side-chain, preferably a cyclic structure such as Phg, Bip, 1Nal, 2Nal, Amc, PheF5, Igl (L-2-indanylglycine) or Cha (L-cyclohexylalanine), preferably Dpa. In some embodiments, A4 contains the betahomo form of the above bulky hydrophobic amino acids, e.g. bhPhe, or bhDpa. Other modifications to the side-chain include aromatic substituents such as those disclosed in Wang et al. (2002) Tetrahedron 58:3101-3110 and Wang et al. (2002) Tetrahedron 58:7365-7374. In some embodiments, the A4 residue is a D-amino acid.

In some embodiments, the amino acid at position A9 is a bulky hydrophobic amino acid such as Phe, Tyr, Trp, Leu, or Ile or any unnatural amino acid commonly used as a substitute thereof that contains 4 or more carbons in its side-chain, preferably a cyclic structure such as Phg, Dpa, Bip, 1Nal, 2Nal, Amc, PheF5, Igl or Cha, such as a cyclic or aromatic group containing 1 or more rings or aromatic substituents. In some embodiments, the A9 residue is Dpa or Trp.

In some embodiments, the mini-hepcidins of the present invention are modified or formulated in order to maintain and/or increase its in vivo bioavailability. For example, in some embodiments, the peptide chain is conjugated with an acyl chain. In some embodiments, the acyl chain may be conjugated to the N-terminal or C-terminal amino acid or a Cysteine residue. In some embodiments, the acyl chain is conjugated to the A7 residue. The acyl chain may include a fatty acid such as caprylic, capric, lauric, myristic, palmitic, or stearic. The acyl chain also may also contain a spacer such as a polyethylene glycol spacer. In some embodiments, the spacer is a polyethylene glycol spacer (1-11 PEG), preferably PEG3 or PEG11. In some embodiments, the spacer comprises of an amino acid where the number of carbons between the amino group and the carboxylic acid group is separated by about 2-8 carbons, such as 6-aminohexanoic acid (see, for example, PR73). Other suitable spacers include a hydrophobic structure that has a ring and/or aromatic character (see, for example, PR74).

The modified mini-hepcidins were demonstrated in a mouse hemochromatosis model that daily administration of the modified mini-hepcidins, e.g. PR65, prevented iron overload. Therefore, the modified mini-hepcidins according to the present invention, alone or in combination with one or more original mini-hepcidins, may be administered to subjects in order to treat, e.g. inhibit and/or reduce, iron overload in subjects, such as humans. Therefore, modified and original mini-hepcidins according to the present invention may be used in medicaments and treatments in order to treat iron overload disorders, e.g. beta-thalassemia and hereditary hemochromatosis, by inhibiting and/or reducing iron overload in subjects. In some embodiments, at least one modified mini-hepcidin and/or at least one original mini-hepcidin is administered to subjects before, during, after, or a combination thereof, symptoms of iron overload are observed and/or being diagnosed as having an iron overload disorder.

Thus, in some embodiments, one or more modified mini-hepcidins, alone or in combination with one or more original mini-hepcidins, are provided in the form of a composition which comprises a carrier suitable for its intended purpose. The compositions may also include one or more additional ingredients suitable for its intended purpose. For example, for assays, the compositions may comprise liposomes, niclosamide, SL220 solubilization agent (NOF, Japan), cremophor EL (Sigma), ethanol, and DMSO. For treatment of an iron overload disease, the compositions may comprise different absorption enhancers and protease inhibitors, solid microparticles or nanoparticles for peptide encapsulation (such as chitosan and hydrogels), macromolecular conjugation, lipidization and other chemical modification.

The present invention also provides kits comprising one or more modified mini-hepcidins, alone or in combination with one or more original mini-hepcidins, and/or compositions of the present invention packaged together with reagents, devices, instructional material, or a combination thereof. For example, the kits may include reagents used for conducting assays, drugs and compositions for diagnosing, treating, or monitoring disorders of iron metabolism, devices for obtaining samples to be assayed, devices for mixing reagents and conducting assays, and the like.

As the peptides of the present invention exhibit hepcidin activity, i.e. act as agonists of ferroportin degradation, one or more modified mini-hepcidins, alone or in combination with one or more original mini-hepcidins, may be used to treat iron overload diseases. For example, one or more modified mini-hepcidins, alone or in combination with one or more original mini-hepcidins, may be administered to a subject to ameliorate the symptoms and/or pathology associated with iron overload in iron-loading anemias (especially β-thalassemias) where phlebotomy is contraindicated and iron chelators are the mainstay of treatment but are often poorly tolerated. One or more modified mini-hepcidins, alone or in combination with one or more original mini-hepcidins, may be used to treat hereditary hemochromatosis, especially in subjects who do not tolerate maintenance phlebotomy. One or more modified mini-hepcidins, alone or in combination with one or more original mini-hepcidins, may be used to treat acute iron toxicity. In some embodiments, treatment with one or more modified mini-hepcidins, alone or in combination with one or more original mini-hepcidins, may be combined with phlebotomy or chelation.

Thus, one or more modified mini-hepcidins, alone or in combination with one or more original mini-hepcidins may be administered to a subject, preferably a mammal such as a human. In some embodiments, the administration to the subject is before, during, and/or after the subject exhibits an increase in iron levels and/or abnormally high levels of iron. In some embodiments, the subject to be treated is one who is at risk of having high levels of iron and/or has a genetic predisposition to having an iron overload disease. In some embodiments, the peptides are administered in a form of a pharmaceutical composition. In some embodiments, the peptides are administered in a therapeutically effective amount. As used herein, a “therapeutically effective amount” is an amount which ameliorates the symptoms and/or pathology of a given disease of iron metabolism as compared to a control such as a placebo.

A therapeutically effective amount may be readily determined by standard methods known in the art. The dosages to be administered can be determined by one of ordinary skill in the art depending on the clinical severity of the disease, the age and weight of the subject, or the exposure of the subject to iron. Preferred effective amounts of mini-hepcidins range from about 0.01 to about 10 mg/kg body weight, about 0.01 to about 3 mg/kg body weight, about 0.01 to about 2 mg/kg, about 0.01 to about 1 mg/kg, or about 0.01 to about 0.5 mg/kg body weight for parenteral formulations. Effective amounts for oral administration may be up to about 10-fold higher. Moreover, treatment of a subject with a peptide or composition of the present invention can include a single treatment or, preferably, can include a series of treatments. It will be appreciated that the actual dosages will vary according to the particular peptide or composition, the particular formulation, the mode of administration, and the particular site, host, and disease being treated. It will also be appreciated that the effective dosage used for treatment may increase or decrease over the course of a particular treatment. Optimal dosages for a given set of conditions may be ascertained by those skilled in the art using conventional dosage-determination tests in view of the experimental data for a given peptide or composition. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some conditions chronic administration may be required.

The pharmaceutical compositions of the invention may be prepared in a unit-dosage form appropriate for the desired mode of administration. The compositions of the present invention may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous and intradermal). A variety of administration routes can be used in accordance with the present invention, including oral, topical, transdermal, nasal, pulmonary, transpercutaneous (wherein the skin has been broken either by mechanical or energy means), rectal, buccal, vaginal, via an implanted reservoir, or parenteral. Parenteral includes subcutaneous, intravenous, intramuscular, intraperitoneal, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques, as well as injectable materials (including polymers) for localized therapy. In some embodiments, the route of administration is subcutaneous. In some embodiments, the composition is in a sealed sterile glass vial. In some embodiments, the composition contains a preservative. Pharmaceutical compositions may be formulated as bulk powder, tablets, liquids, gels, lyophilized, and the like, and may be further processed for administration. See e.g. REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY. 20^(th) ed. (2000) Lippincott Williams & Wilkins. Baltimore, Md., which is herein incorporated by reference.

It will be appreciated that the preferred route will vary with the condition and age of the recipient, the nature of the condition to be treated, and the chosen peptide and composition.

Pharmaceutical compositions of the present invention comprise a therapeutically effective amount of at least one peptide as disclosed herein, and a pharmaceutically acceptable carrier or diluent, which may be inert. As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, bulking agent, coatings, antibacterial and antifungal agents, preservatives, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration and known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.

Supplementary compounds can also be incorporated into the compositions. Supplementary compounds include niclosamide, liposomes, SL220 solubilization agent (NOF, Japan), Cremophor EL (Sigma), ethanol, and DMSO.

Toxicity and therapeutic efficacy of the peptides and compositions of the present invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Peptides which exhibit large therapeutic indices are preferred. While peptides that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such peptides to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of peptides of the present invention lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any peptide used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography or by mass spectroscopy.

Modified Mini-Hepcidin, PR65

Peptide Synthesis.

Modified mini-hepcidins according to the present invention were synthesized using standard solid-phase fmoc chemistry and was purified by reverse-phase HPLC. For PR65, from A1 to A9 of Structural Formula IA (i.e. from the N to C terminus) the primary sequence was all L-amino acids as follows: iminodiacetic acid, threonine, histidine, diphenylalanine, beta-homo proline, arginine, cysteine, arginine and beta-homo phenylalanine. The C-terminal carboxyamide was derivatized with a polyethylene glycol (PEG) linker and palmitic acid groups (FIG. 10A). Human hepcidin was purchased from Peptides International (Louisville, Ky.).

Animal Studies.

All studies were approved by the UCLA Office of Animal Research Oversight. Six weeks old male wild-type C57BL/6 mice were used to compare the activities of native hepcidin and PR65, and to test the effect of PR65 after intraperitoneal versus subcutaneous route of administration. Hepcidin and PR65 were administered in 100 μl of SL220, a PEG-phospholipid based solubilizer (NOF Corporation, Japan) (Preza G C, et al. (2011) J Clin. Invest. 121(12):4880-4888) and iron parameters were measured after 4 hours. This solvent does not significantly change serum iron concentrations in mice (<5 μM change, data not shown).

The therapeutic effects of PR65 was studied in hepcidin-1 knockout mice (Hamp1^(−/−)) (Lesbordes-Brion J C, et al. (2006) Blood 108(4):1402-1405) and backcrossed onto the C57BL/6 background (N4, 99% gene marker identity) using marker-assisted accelerated backcrossing (Charles River Laboratories, Wilmington, Mass.). PR65 was administered subcutaneously in 100 μl of SL220 solubilizer. Short-term studies were carried out for up to 48 hours to establish the effectiveness of a single injection. Long-term studies (“prevention” and “treatment”) were carried out for 2 weeks using daily injections and iron and hematological parameters measured 24 hours after the last injection.

To test the ability of PR65 to prevent, inhibit, or reduce iron loading (“prevention” studies), male Hamp1^(−/−) mice were iron-depleted by placing them on a low-iron diet (4 ppm iron) for 2 months starting at the age of 5-6 weeks. The regimen was developed to match the hepatic iron content of wild-type C57B6 mice, about 2-3 μmoles/g wet liver (Ramos E, et al. (2011) Hepatology 53(4):1333-1341). A group of mice was analyzed immediately after iron depletion (baseline group), and the remaining animals were switched to an iron-loading diet (standard chow, about 300 ppm Fe) and received daily subcutaneous injection of solvent or PR65 (20, 50 or 100 nmoles) for 2 weeks. All mouse diets were obtained from Harlan-Teklad (Madison, Wis.).

To test the effect of PR65 on iron-loaded Hamp1^(−/−) mice (“treatment” studies), male mice were kept on the standard diet for their entire lifespan. Beginning at 12-14 weeks of age, 50 nmoles of PR65 or solvent was injected daily by the subcutaneous route for 2 weeks.

Measurement of Iron and Hematological Parameters.

Serum iron and non-heme iron concentrations were determined as previously described (Ramos E, et al. (2011) Hepatology 53(4):1333-1341), using acid treatment followed by a colorimetric assay for iron quantitation (Genzyme, Cambridge, Mass.). Deparaffinized sections were stained with the Perls Prussian blue stain for non-heme iron, enhanced with the SG peroxidase substrate kit (Vector Labs, Burlingame, Calif.) and counterstained with nuclear fast red. Complete blood counts were obtained with a HemaVet blood analyzer (Drew Scientific, Oxford, Conn.).

Statistical Analysis.

The statistical significance of differences between group means was evaluated using Student T-test and the Sigmaplot 11.0 package (Systat Software, San Jose, Calif.).

Mini-Hepcidin Treatment Regimen

PR65 (FIG. 10A) was selected for the prevention and treatment studies in hepcidin-null mice based on pilot studies in wild-type C57BL/6 mice. PR65 was found to be among the most potent mini-hepcidins and its molar bioactivity after intraperitoneal injection was comparable to that of native hepcidin (FIG. 10B). Moreover, PR65 retained full activity with subcutaneous as compared to intraperitoneal administration (FIG. 10C) and its cost of synthesis was favorable compared to other mini-hepcidins. Based on qualitative assessment of more than 80 mini-hepcidins, the high bioactivity of PR65 compared to the prototypical peptide containing the 9 N-terminal amino acids of human hepcidin (SEQ ID NO:9) is likely due to increased aromaticity, solubility, resistance to proteolysis, as well as lower renal clearance due to increased plasma protein binding mediated by the palmitoyl group.

To establish optimal dosing parameters for a long-term mini-hepcidin treatment regimen, dose-response (FIG. 11A) and time course (FIG. 11B) experiments in iron-loaded hepcidin knockout mice, Hamp1−/− mice, was performed. After 24 hours, subcutaneous injection of 20 and 50 nmoles of PR65 caused 15% and 10% (p=0.005, p=0.004) decreases in serum iron, while 100 and 200 nmole doses resulted in an 85% and 95% reduction (p<0.001 for both). Because 100 nmoles of PR65 produced a near maximal hypoferremia, this dose was selected for a time course experiment to determine the timing and duration of its peak effect. The maximal drop (88%) in serum Fe occurred 12 hours after subcutaneous injection (p<0.001), and serum Fe remained severely suppressed (82%) at 24 hours but returned to solvent control levels 48 hours after injection.

The activity of PR65 (100 nmoles) was also assessed over 48 hours through its effect on tissue iron retention. Interestingly, spleen iron accumulation was not observed during 48 hours after PR65 injection (FIG. 12). This is likely because the spleen in hepcidin knockout mice is completely depleted of iron and it takes more than 2 days to accumulate enough iron so it is conclusively detectable by enhanced Perls stain. Liver iron content, which was already high in these mice, did not visibly change through the course of the experiment. From 1-4 hours after injection, duodenal sections showed distinct iron staining around villous capillary networks indicating continued high ferroportin activity and uncurbed iron transfer to plasma. From 12-24 hours after PR65 injection, iron accumulated within enterocytes consistent with the expected mini-hepcidin-induced loss of ferroportin and diminished iron transfer to plasma. As the mini-hepcidin effect wore off 48 hours after injection, iron was no longer retained in enterocytes.

Thus, in some embodiments, subjects are treated with a given does, e.g. about 100 μg/kg, of a mini-hepcidin daily, and after about one week, the dose is halved if the subject's serum iron concentration is below about 10 μM or doubled if serum iron is above about 30 μM. At about the beginning of the third week of treatment, the dose may be increased or decreased by about 25-50% to maintain serum iron levels between about 10-30 μM. In some embodiments, after about 1 week of administration of one or more mini-hepcidins, the iron levels, and/or ferroportin, and/or mini-hepcidin levels in the subject may be monitored using methods known in the art or as disclosed herein, and then based on the levels, the subject may be treated accordingly, e.g. administered one or more subsequent doses of one or more mini-hepcidins which may be higher or lower than the initial dose. The mini-hepcidins of the subsequent doses may be the same or different from the mini-hepcidins of the first dose.

Chronic Administration of Mini-Hepcidin Prevents Iron Loading in Hepcidin Deficient Subjects

The ability of PR65 to prevent iron loading in hepcidin in subjects was examined using mice as models. Hepcidin KO mice were placed on an iron-deficient diet for 8 weeks to lower their iron stores to a level comparable to that of WT mice. After iron depletion, a group of mice was analyzed to establish the baseline iron and hematological parameters and the rest of the mice were placed on an iron-loading diet (300 ppm Fe) for 2 weeks while simultaneously receiving daily subcutaneous injections of solven only (control) or PR65 (20, 50 or 100 nmoles) in solvent. It was hypothesized that in comparison to the solvent treatment, PR65 would cause iron retention in the spleen, decrease serum iron and prevent liver iron loading. Because cardiac iron overload is a marker for poor prognosis in iron-loaded patients, heart iron was also measured. Hemoglobin concentrations were monitored to detect potential iron-restrictive effects of hepcidin excess on erythropoiesis.

Hepcidin agonist activity of the mini-hepcidins was confirmed in all treated groups by the increased retention of iron in macrophages manifested as increases in spleen iron content. Compared to the almost undetectable non-heme iron content in solvent-injected control spleens, all three mini-hepcidin doses caused 15- to 30-fold increases in spleen iron content (p=0.01 for all) (FIG. 13A). Serum iron did not change in mice that received 20 nmoles of PR65 daily (p=0.26), but decreased by 69% and 83% in mice that received 50 and 100 nmoles per day (p=0.01 for both) (FIG. 13B). The decrease in circulating iron concentrations was also reflected as dose-dependent 3 and 5 g/dL reductions of hemoglobin concentrations in the 50 and 100 nmoles groups, respectively (p<0.001 for both), but hemoglobin levels did not change significantly at 20 nmoles (p=0.13) (FIG. 13C). Heart iron concentration dropped 33%, 60% and 47% in mice treated with 20, 50 and 100 nmoles of PR65 respectively (p=0.08, 0.007, 0.05) (FIG. 13D). Additionally, mice treated with the three PR65 doses had 76%, 53% and 68% less liver iron than solvent-treated controls (p=0.001, 0.06, 0.01) and no statistically significant increases in liver iron compared to mice from the iron-depleted baseline group. Except for serum iron and hemoglobin, the lack of a consistent dose-response relationship may indicate that the maximum effect was reached at a relatively low dose so that the differences reflect statistical fluctuations (liver and heart iron) or that two or more effects of PR65 interact in a complex manner (splenic iron may reflect the combined effects of decreased iron export from the spleen, decreased iron absorption in the duodenum, and decreased number of erythrocytes all of which are expected effects of PR65).

Perls stains of organ sections from mini-hepcidin-treated mice compared to iron-depleted baseline mice indicated that iron stores in the liver did not increase from baseline in the 20 and 50 nmoles groups, and were even lower than baseline at the 100 nmole dose (FIG. 14). In contrast, liver sections of the solvent-injected mice showed very high iron levels. A similar pattern of differences between the solvent and PR65 groups was observed in the heart, with a complete lack of iron staining in the heart of mice that received 100 nmoles of peptide. Significant accumulation of iron in the red pulp of the spleen was observed in all mini-hepcidin groups, but not in mice that received solvent, or in baseline iron-depleted mice. Duodenal sections at baseline showed no iron staining, while PR65-treated mice showed iron retention in the duodenal enterocytes, again confirming that PR65 blocked iron efflux from enterocytes.

Thus, in some embodiments, the present invention provides methods of preventing iron loading in subjects having abnormally low or no levels of hepcidin which comprises chronic administration of one or more mini-hepcidins according to the present invention.

Mini-Hepcidin Effect in Iron Overloaded Hepcidin Knockout Mice

To assess the potential of mini-hepcidins as a standalone treatment for iron overload in subjects, 12 week old iron-overloaded hepcidin knockout mice were injected with 50 nmoles of PR65 daily for 14 days. This dose was chosen as the maximal tolerated dose because mice that received 100 nmoles in the previous experiment became moderately anemic. Peptide activity was confirmed by the 15-fold increase in spleen iron content (p<0.001) (FIG. 15A). In contrast to mice that were iron-depleted before PR65 administration, in mice with established iron overload serum iron levels were not decreased 24 hours after the last dose compared to solvent-treated mice (p=0.682) (FIG. 15B). However, the 2 g/dL decrease in hemoglobin (p=0.012) (FIG. 15C) suggests that serum iron could have been transiently decreased during the treatment. The less than 24 hours duration of the hypoferremic effect of each 50 nmoles dose may have been due to the severe iron overload of the hepcidin knockout mice at this age. Accumulated hepatocyte iron could stimulate ferroportin synthesis and iron efflux from hepatocytes into plasma by relieving the inhibition of ferroportin translation by iron-regulatory proteins (IRPs) interacting with 5′ iron-regulatory element (5′ IRE) in the ferroportin mRNA, and possibly by other mechanisms. Compared to the control group, iron-loaded mice treated with PR65 showed a trend toward decreased heart iron concentrations (24% decrease, p=0.085) (FIG. 15D), and their liver iron levels decreased by about 20% (p=0.009) or about 200 μg/g (FIG. 15E), an amount equivalent to the total hepatic iron content in wild-type mice.

Enhanced Perls staining demonstrated iron retention in the spleen and duodenum in mice treated with PR65 and a change in the iron distribution pattern in the liver (FIG. 16). No statistically significant differences were noticeable in the heart and pancreas sections of the solvent and PR65-treated mice. In the aggregate, staining and quantitative analysis indicate that the 2-week mini-hepcidin treatment alone could not only inhibit dietary iron absorption but also redistribute a modest amount of iron from the liver to the spleen.

Thus, in some embodiments, human subjects being treated for an iron overload disease are treated with one or more mini-hepcidins for a period of at least the minimum period necessary to detect that the treatment prevented liver iron accumulation by available imaging technologies (e.g. FerriScan), e.g. about three months. In some subjects, the treatment may be continued for many years or for the life of the subject.

As shown in FIG. 13, PR65 acted predominantly by reducing iron absorption but also redistributed iron into splenic macrophages when administered prophylactically. Thus, in some embodiments, one or more mini-hepcidins may be administered to a subject as a prophylactic treatment against iron overload in the subject. For example, where a subject having liver iron that is within a normal range, but has a predisposition for an iron overload disease (e.g. genetically predisposed to excessive iron adsorption), or is at risk of developing an abnormally high level of iron, the subject may be administered one or more mini-hepcidins to prevent and/or reduce the likelihood that the subject will develop an iron overload disease and/or abnormally high levels of iron.

According to FIG. 13, iron distribution was calculated based on the following assumptions and equations: Estimated organ masses based on average weight of 25 g, Blood volume (5.5%)=1.4 ml, Liver mass (5%)=1.3 g, Spleen mass (0.3%)=0.08 g, % Fe in Hb=0.34% based on the molecular mass of Hb=64,000 Dalton and 4 iron atoms with a total atomic mass of 224 Dalton, Total iron in Hb=(Hb concentration)×(Blood volume)×(% Fe in Hb), and Total iron in an organ=molar iron concentration×organ mass×56 g/mole. The amounts for the solvent group and the PR65 group are shown as follows:

TABLE 5 Total organ iron (mg) Solvent treatment Hb = 15 g/dl 0.7 Liver iron concentration = 17 μmoles/g 1.2 Spleen iron concentration = 0.5 μmoles/g 0.002 Total 1.9 PR65: 50 nmoles Hemoglobin = 11.5 g/dl 0.5 Liver iron concentration = 8 μmoles/g 0.6 Spleen iron concentration = 30 μmoles/g 0.1 Total 1.2 (36% decrease)

The resulting decrease of plasma iron could also reduce the levels of toxic non-transferrin bound iron (NTBI) and promote the mobilization of iron from the heart and endocrine organs where iron excess is not tolerated. Thus, in some embodiments, one or more mini-hepcidins may be administered to a subject in order to reduce the levels of NTBI and/or promote the mobilization of iron from the heart and endocrine organs to other organs and tissues.

Unlike phlebotomy or chelation, mini-hepcidins would not be expected to appreciably increase iron losses from the body. In a relatively mild model of iron overload in HFE null mice (Viatte L, et al. (2006) Blood 107(7):2952-2958), transgenic hepcidin expression was reported to cause significant redistribution of iron into hepatic macrophages, a location where iron accumulation is relatively nontoxic. In more overloaded Hamp1^(−/−) mice, red pulp macrophages in mini-hepcidin-treated mice retained iron but the small resulting decrease in liver and heart iron stores suggests that mini-hepcidins alone confer a modest therapeutic benefit once the liver iron burden is high. The shorter than 24 hour effect of a mini-hepcidin dose on transferrin saturation in this severe iron overload model may imply that NTBI continues to deliver iron to parenchymal organs counteracting the effects of iron redistribution to macrophages and decreased iron absorption.

Therefore, in established iron overload in human subjects, effective treatment with one or more mini-hepcidins may include more than one dose per day, a prolonged treatment period before a beneficial effect in liver iron can be detected, or may be combined with removal of iron by phlebotomy or chelation.

Dosages

The exclusive use of L-amino acids in PR65 was found to significantly reduce peptide production costs. In addition, the unnatural and highly aromatic residues in PR65 were unexpectedly found to substantially reduce the minimal effective dose in mice to 20 nmoles/d or 1.3 mg/kg/d.

According to U.S. Food and Drug Administration dosing adjustment guidelines, the difference in metabolic rates between the mouse and human requires a conversion based on the Km factor which normalizes doses to body surface area (Reagan-Shaw S, et al. (2008) FASEB J 22(3):659-661). A human equivalent dose (HED) can be estimated by HED=animal dose (mg/kg)×(animal Km/human Km), where the Km for mouse and an adult human are 3 and 37, respectively. Thus, according to the present invention, a subcutaneous dose of mini-hepcidin in a human could be up to about 50-100 μg/kg/d, about 75-125 μg/kg/d, or about 90-110 μg/kg/d, preferably about 100 μg/kg/d (as this dose is a readily administrable amount of peptide about three times the median basal dose of the most widely used peptide drug, subcutaneous insulin, commonly used at 0.75 U/kg/d or 33 μg/kg/d in type 2 diabetics (Rosenstock J, et al. (2001) Diabetes Care 24(4):631-636)). Of course, lower doses, as well as higher doses, depending on the particular mini-hepcidin, form of administration, formulation, the subject and the degree of iron overload, may be administered to subject.

Important differences between murine and human iron metabolism that could alter the effect of a mini-hepcidin, e.g. PR65, in humans include the somewhat longer lifetime of human erythrocytes (120 days vs 40 days) and the much lower fractional iron losses in humans (daily iron losses compared to total body iron) as estimated from the slower depletion of iron stores on iron-deficient diets (in males: 300-600 days vs 15-20 days). The net effect of these differences is the much lower contribution of intestinal iron absorption to the daily iron flux in humans (4-8% compared to more than 50% in mice) (Ramos E, et al. (2011) Hepatology 53(4):1333-1341). If hepcidin and its analogs exert stronger effects on macrophages than on enterocytes (Reagan-Shaw S, et al. (2008) FASEB J 22(3):659-661) this could further decrease the relative doses of mini-hepcidins required for a similar hypoferremic effect in humans. Thus, in some embodiments, a therapeutically effective dose of one or more mini-hepcidins ranges from about 10-500 μg/kg/d. Again, lower doses, as well as higher doses, depending on the particular mini-hepcidin, form of administration, formulation, the subject and the degree of iron overload, may be administered to subject.

As provided herein, mini-hepcidins according to the present invention may be used to inhibit, reduce, or treat iron overload in subjects at risk due to genetic defects or those who have already undergone iron depletion, but no longer tolerate chelation or venesection therapy. The mini-hepcidins according to the present invention may be used to treat a subject having β-thalassemia major and/or a subject having hepcidin levels that are higher than normal but are lower than what is appropriate for the degree of iron overload and the particular subject. For example, one or more min-hepcidins according to the present invention may be used to treat a subject who suffers from hyperabsorption of dietary iron, but has normal levels of iron, in order to lower the amount of iron in the subject and offset the hyperabsorption. One or more mini-hepcidins according to the present invention may be used to treat ineffective erythropoiesis and improve anemia in subjects.

Because of the relatively small size of the mini-hepcidins of the present invention, the mini-hepcidins may be appropriately formulated and optimized for oral administration or administration by other noninvasive means such as those used for insulin administration (Roach P. (2008) Clinical Pharmacokinetics 47(9):595-610) such as inhalation, or transcutaneous delivery, or mucosal nasal or buccal delivery.

To the extent necessary to understand or complete the disclosure of the present invention, all publications, patents, and patent applications mentioned herein are expressly incorporated by reference therein to the same extent as though each were individually so incorporated.

Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only and that various other alternatives, adaptations, and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is only limited by the following claims. 

We claim:
 1. An isolated peptide having the following structural formula IA or IB A1-A2-A3-A4-A5-A6-A7-A8-A9-A10  IA A10-A9-A8-A7-A6-A5-A4-A3-A2-A1  IB wherein A1 is Asp, D-Asp, Glu, D-Glu, pyroglutamate, D-pyroglutamate, Gln, D-Gln, Asn, D-Asn, bhAsp, Ida, Ida(NHPal), or N-MeAsp; A2 is Thr, D-Thr, Ser, D-Ser, Val, D-Val, Ile, D-Ile, Ala, D-Ala, Tle, Inp, Chg, bhThr, or N-MeThr; A3 is His, D-His, Asn, D-Asn, Arg, D-Arg, L-His(π-Me), D-His(π-Me), L-His(τ-Me), or D-His(τ-Me); A4 is Phe, D-Phe, Leu, D-Leu, Ile, D-Ile, Trp, D-Trp, Tyr, D-Tyr, Phg, bhPhe, Dpa, Bip, 1Nal, 2Nal, bhDpa, Amc, PheF5, hPhe, Igl, or cyclohexylalanine; A5 is Pro, D-Pro, Ser, D-Ser, Oic, bhPro, trans-4-PhPro, cis-4-PhPro, cis-5-PhPro, or Idc; A6 is Arg, L-Nω,ω-dimethyl-arginine, L-homoarginine, L-norarginine, citrulline, or N-MeArg; A7 is Cys, D-Cys, Ser, D-Ser, Ala, D-Ala, Cys(S-tBut), homoCys, Pen, (D)Pen, S-tertiary butyl-cysteine, Cys(S-S-Pal), Cys(S-S-cysteamine-Pal), Cys(S-S-Cys-NHPal), or Cys(S-S-Cys); A8 is Arg, L-Nω,ω-dimethyl-arginine, L-homoarginine, L-norarginine, citrulline, or N-MeArg; A9 is Phe, D-Phe, Leu, D-Leu, Ile, D-Ile, Tyr, D-Tyr, Trp, D-Trp, Phe-R^(a), D-Phe-R^(a), Dpa-R^(a), D-Dpa-R^(a), Trp-R^(a), bhPhe-R^(a), PheF5, N-MePhe, benzylamide, 2-aminoindane, bhPhe, Dpa, Bip, 1Nal, 2Nal, bhDpa, or cyclohexylalanine, which may or may not have R^(a) linked thereto, wherein R^(a) is palmitoyl-PEG- wherein PEG is PEG11 or miniPEG3, palmitoyl-PEG-PEG11, palmitoyl-PEG-miniPEG3, butanoyl (C4)-PEG11-, octanoyl (C8, Caprylic)-PEG11-, palmitoyl (C16)-PEG11-, or tetracosanoyl (C24, Lignoceric)-PEG11-; and A10 is Cys, D-Cys, Ser, D-Ser, Ala, D-Ala, Ida, Ahx-Ida(NHPal), or Ahx-Ida(NBzl2); wherein the carboxy-terminal amino acid is in amide or carboxy-form; wherein at least one sulfhydryl amino acid is present as one of the amino acids in the sequence; and wherein A1, A1 to A2, A10, or a combination thereof are optionally absent, and wherein bhAsp is 3-aminopentanedioic acid Ida is 2,2′-azanediyldiacetic acid; Ida(NHPal) is a palmitylamine amide on Ida side chain; Ida(NBzl2) is N,N′-Dibenzylamine amide on Ida side chain; N-MeAsp is methyl-L-aspartic acid; Ahx is aminohexanoic acid; Tle is L-tert-leucine; Inp is isonipecotic acid; Chg is L-α-cyclohexylglycine; bhThr is β-homothreonine; N-MeThr is (2S)-3-hydroxy-2-(methylamino)butanoic acid; His(π-Me) is N^(π)-methylhistidine; His(τ-Me) is N^(τ)-methylhistidine; Phg is L-phenylglycine; bhPhe is β-homophenylalanine; Dpa is 3,3-diphenyl-L-alanine; Bip is L-biphenylalanine; 1Nal is (1-naphthyl)-L-alanine; 2Nal is (2-naphthyl)-L-alanine; bhDpa is (S)-3-Amino-4,4-diphenylbutanoic acid; Amc is 4-(aminomethyl)cyclohexane carboxylic acid; PheF5 is (R)-2-amino-3-(perfluorophenyl)propanoic acid; hPhe is (S)-2-amino-4-phenylbutanoic acid; Igl is (S)-2-amino-2-(2,3-dihydro-1H-inden-2-yl)acetic acid; Oic is octahydroindole-2-carboxylic acid; bhPro is L-β-homoproline; trans-4-PhPro is (2S,4S)-4-phenylpyrrolidine-2-carboxylic acid; cis-4-PhPro is (2S,4R)-4-phenylpyrrolidine-2-carboxylic acid; cis-5-PhPro is (2R,5S)-5-phenylpyrrolidine-2-carboxylic acid; Idc is (R)-indoline-2-carboxylic acid; Cys(S-tBut) is S-t-Butylthio-L-cysteine; homoCys is L-homocysteine; Pen is L-Penicillamine; (D)Pen is D-Penicillamine; Cys(S-S-Pal) is palmitoyl attached to Cys via a disufide bond; Cys(S-S-cysteamine-Pal) is palmitoyl attached to Cys via SS-Cysteamine; Cys(S-S-Cys-NHPal) is palmitylamine attached to Cys via another Cys; Cys(S-S-Cys) is Cys attached to Cys via disulfide bond; N-MeArg is N^(ω)-methyl-L-arginine; PEG11 is O-(2-aminoethyl)-O′-(2-carboxyethyl)-undecaethyleneglycol; and miniPEG3 is 11-amino-3,6,9-trioxaundecanoic acid.
 2. The peptide according to claim 1, wherein the peptide contains at least one of the following: a) A1=N-MeAsp, Ida, or Ida(NHPal); b) A5=bhPro; c) A6=Arg, or N-MeArg; d) A7=Cys(S-S-Pal), Cys(S-S-cysteamine-Pal), Cys(S-S-Cys-NHPal), or Cys(S-S-Cys); and/or e) A8=Arg, or N-MeArg.
 3. The peptide according to claim 1, wherein: i) when A1 is Ida and A9 is Phe, then A10 is not Ahx-Ida(NHPal); ii) when A1 is Ida, A9 is not bhPhe-R^(b), wherein R^(b) is S-(palmityl)thioglycolic-PEG-; iii) when A4 is D-Phe, A7 is not D-Cys(S-S-tBut) and A9 is not D-Trp-R^(c), wherein R^(c) is Butanoyl-PEG11-, Octanoyl-PEG11-, Palmitoyl-PEG11-, or Tetracosanoyl-PEG11-.
 4. The peptide according to claim 1, wherein A1 is D-Asp, N-MeAsp, Ida, or Ida(NHPal); A2 is Thr or D-Thr; A3 is His or D-His; A4 is Dpa or D-Dpa; A5 is Pro, D-Pro, bhPro, or Oic; A6 is Arg, or N-MeArg; A7 is Cys, D-Cys, Cys(S-S-Pal), Cys(S-S-cysteamine-Pal), Cys(S-S-Cys-NHPal), or Cys(S-S-Cys); A8 is Arg, or N-MeArg; A9 is Phe, D-Phe, Dpa, D-Dpa, Trp, D-Trp, bhPhe, Phe-R^(a), D-Phe-R^(a), Dpa-R^(a), D-Dpa-R^(a) bhPhe-R^(a), where in R^(a) is palmitoyl-PEG- wherein PEG is PEG11 or miniPEG3, palmitoyl-PEG-PEG wherein PEG is PEG11 or miniPEG3, butanoyl (C4)-PEG11-, octanoyl (C8, Caprylic)-PEG11-, palmitoyl (C16)-PEG11-, or tetracosanoyl (C24, Lignoceric)-PEG11-; and A10, if present, is Ahx-Ida(NHPal) or Adx-Ida(NBzl2).
 5. The peptide of according to claim 1, wherein the peptide is selected from the group consisting of: Asp-Thr-His-Dpa-Pro-Arg-Cys-Arg-Dpa (SEQ ID NO: 67), N-MeAsp-Thr-His-Dpa-Oic-Arg-Cys-Arg-bhPhe-R14 (SEQ ID NO: 77), N-MeAsp-Thr-His-Dpa-bhPro-Arg-Cys-Arg-bhPhe-R14 (SEQ ID NO: 78), Ida-Thr-His-Dpa-bhPro-Arg-Cys-Arg-bhPhe-R14 (SEQ ID NO: 82), Ida-Thr-His-Dpa-bhPro-Arg-Cys-Arg-bhPhe-R15 (SEQ ID NO: 86), Ida-Thr-His-Dpa-bhPro-Arg-Cys-Arg-bhPhe (SEQ ID NO:87), Ida-Thr-His-Dpa-bhPro-Arg-Cys(S-S-Pal)-Arg-bhPhe (SEQ ID NO: 88), Ida-Thr-His-Dpa-bhPro-Arg-Cys(S-S-cysteamine-Pal)-Arg-bhPhe (SEQ ID NO: 89), Ida-Thr-His-Dpa-bhPro-Arg-Cys(S-S-Cys-NHPal)-Arg-bhPhe (SEQ ID NO: 90), Ida-Thr-His-Dpa-bhPro-Arg-Cys(S-S-Cys)-Arg-bhPhe-R14 (SEQ ID NO: 91), Ida(NHPal)-Thr-His-Dpa-bhPro-Arg-Cys-Arg-bhPhe (SEQ ID NO: 92), Ida-Thr-His-Dpa-bhPro-Arg-Cys-Arg-bhPhe-Ida(NHPal) (SEQ ID NO:93), Ida-Thr-His-Dpa-bhPro-Arg-Cys-Arg-bhPhe-Ahx-lda(NBzl2) (SEQ ID NO: 95), and Ida-Thr-His-Dpa-bhPro-Arg-Cys-Arg-Trp-Ahx-Ida(NHPal) (SEQ ID NO: 101), wherein Ahx is an aminohexanoic acid spacer between peptide residue 9 and Ida residue; R14 is Palmitoyl-PEG-miniPEG3-, and miniPEG3 is 11-amino-3,6,9-trioxaundecanoic acid; and R15 is Palmitoyl-PEG-.
 6. The peptide according to claim 1, wherein the peptide exhibits hepcidin activity.
 7. The peptide according to claim 1, wherein the peptide binds ferroportin.
 8. A composition which comprises at least one peptide according to claim
 1. 9. A method of binding a ferroportin or inducing ferroportin internalization and degradation which comprises contacting the ferroportin with at least one peptide according to claim 1 or a composition comprising the at least one peptide.
 10. A method of treating a disease of iron metabolism in a subject which comprises administering at least one peptide according to claim 1 or a composition comprising the at least one peptide to the subject.
 11. The method of claim 10, wherein the disease of iron metabolism is an iron overload disease.
 12. A kit comprising at least one peptide according to claim 1 or a composition comprising the at least one peptide packaged together with a reagent, a device, instructional material, or a combination thereof.
 13. A complex comprising at least one peptide according to claim 1 bound to a ferroportin or an antibody.
 14. The method according to claim 10, wherein the at least one peptide is administered at an effective daily dose as a single daily dose or as divided daily doses.
 15. The method according to claim 14, wherein the effective daily dose is about 10-500 μg/kg/day and the at least one peptide is provided in a formulation for subcutaneous injection.
 16. The method according to claim 14, wherein the effective daily dose is about 10-1000 μg/kg/day and the at least one peptide is provided in a formulation for oral, pulmonary, parenteral, or mucosal administration.
 17. An isolated peptide having the following structural formula IA or IB A1-A2-A3-A4-A5-A6-A7-A8-A9-A10  IA A10-A9-A8-A7-A6-A5-A4-A3-A2-A1  IB wherein A1 is Asp, D-Asp, Glu, D-Glu, pyroglutamate, D-pyroglutamate, Gln, D-Gln, Asn, D-Asn, bhAsp, Ida, Ida(NHPal), or N-MeAsp; A2 is Thr, D-Thr, Ser, D-Ser, Val, D-Val, Ile, D-Ile, Ala, D-Ala, Tle, Inp, Chg, bhThr, or N-MeThr; A3 is His, D-His, Asn, D-Asn, Arg, D-Arg, L-His(π-Me), D-His(π-Me), L-His(τ-Me), or D-His(τ-Me); A4 is Phe, D-Phe, Leu, D-Leu, Ile, D-Ile, Trp, D-Trp, Tyr, D-Tyr, Phg, bhPhe, Dpa, Bip, 1Nal, 2Nal, bhDpa, Amc, PheF5, hPhe, Igl, or cyclohexylalanine; A5 is Pro, D-Pro, Ser, D-Ser, Oic, bhPro, trans-4-PhPro, cis-4-PhPro, cis-5-PhPro, or Idc; A6 is Arg; A7 is Cys, D-Cys, Ser, D-Ser, Ala, D-Ala, Cys(S-tBut), homoCys, Pen, (D)Pen, S-tertiary butyl-cysteine, Cys(S-S-Pal), Cys(S-S-cysteamine-Pal), Cys(S-S-Cys-NHPal), or Cys(S-S-Cys); A8 is Arg; A9 is Phe, D-Phe, Leu, D-Leu, Ile, D-Ile, Tyr, D-Tyr, Trp, D-Trp, Phe-R^(a), D-Phe-R^(a), Dpa-R^(a), D-Dpa-R^(a), Trp-R^(a), bhPhe-R^(a), PheF5, N-MePhe, benzylamide, 2-aminoindane, bhPhe, Dpa, Bip, 1Nal, 2Nal, bhDpa, or cyclohexylalanine, which may or may not have R^(a) linked thereto, wherein R^(a) is palmitoyl-PEG- wherein PEG is PEG11 or miniPEG3, palmitoyl-PEG-PEG11, palmitoyl-PEG-miniPEG3, butanoyl (C4)-PEG11-, octanoyl (C8, Caprylic)-PEG11-, palmitoyl (C16)-PEG11-, or tetracosanoyl (C24, Lignoceric)-PEG11-; and A10 is Cys, D-Cys, Ser, D-Ser, Ala, D-Ala, Ida, Ahx-Ida(NHPal), or Ahx-Ida(NBzl2); wherein the carboxy-terminal amino acid is in amide or carboxy-form; wherein at least one sulfhydryl amino acid is present as one of the amino acids in the sequence; and wherein A1, A1 to A2, A10, or a combination thereof are optionally absent, and wherein bhAsp is 3-aminopentanedioic acid Ida is 2,2′-azanediyldiacetic acid; Ida(NHPal) is a palmitylamine amide on Ida side chain; Ida(NBzl2) is N,N′-Dibenzylamine amide on Ida side chain; N-MeAsp is methyl-L-aspartic acid; Ahx is aminohexanoic acid; Tle is L-tert-leucine; Inp is isonipecotic acid; Chg is L-α-cyclohexylglycine; bhThr is β-homothreonine; N-MeThr is (2S)-3-hydroxy-2-(methylamino)butanoic acid; His(π-Me) is N^(π)-methylhistidine; His(τ-Me) is N^(τ)-methylhistidine; Phg is L-phenylglycine; bhPhe is β-homophenylalanine; Dpa is 3,3-diphenyl-L-alanine; Bip is L-biphenylalanine; 1Nal is (1-naphthyl)-L-alanine; 2Nal is (2-naphthyl)-L-alanine; bhDpa is (S)-3-Amino-4,4-diphenylbutanoic acid; Amc is 4-(aminomethyl)cyclohexane carboxylic acid; PheF5 is (R)-2-amino-3-(perfluorophenyl)propanoic acid; hPhe is (S)-2-amino-4-phenylbutanoic acid; Igl is (S)-2-amino-2-(2,3-dihydro-1H-inden-2-yl)acetic acid; Oic is octahydroindole-2-carboxylic acid; bhPro is L-β-homoproline; trans-4-PhPro is (2S,4S)-4-phenylpyrrolidine-2-carboxylic acid; cis-4-PhPro is (2S,4R)-4-phenylpyrrolidine-2-carboxylic acid; cis-5-PhPro is (2R,5S)-5-phenylpyrrolidine-2-carboxylic acid; Idc is (R)-indoline-2-carboxylic acid; Cys(S-tBut) is S-t-Butylthio-L-cysteine; homoCys is L-homocysteine; Pen is L-Penicillamine; (D)Pen is D-Penicillamine; Cys(S-S-Pal) is palmitoyl attached to Cys via a disufide bond; Cys(S-S-cysteamine-Pal) is palmitoyl attached to Cys via SS-Cysteamine; Cys(S-S-Cys-NHPal) is palmitylamine attached to Cys via another Cys; Cys(S-S-Cys) is Cys attached to Cys via disulfide bond; N-MeArg is N^(ω)-methyl-L-arginine; PEG11 is O-(2-aminoethyl)-O′-(2-carboxyethyl)-undecaethyleneglycol; and miniPEG3 is 11-amino-3,6,9-trioxaundecanoic acid.
 18. An isolated peptide consisting of the following structural formula IA or IB A1-A2-A3-A4-A5-A6-A7-A8-A9-A10  IA A10-A9-A8-A7-A6-A5-A4-A3-A2-A1  IB wherein A1 is Asp, D-Asp, Glu, D-Glu, pyroglutamate, D-pyroglutamate, Gln, D-Gln, Asn, D-Asn, bhAsp, Ida, Ida(NHPal), or N-MeAsp; A2 is Thr, D-Thr, Ser, D-Ser, Val, D-Val, Ile, D-Ile, Ala, D-Ala, Tle, Inp, Chg, bhThr, or N-MeThr; A3 is His, D-His, Asn, D-Asn, Arg, D-Arg, L-His(π-Me), D-His(π-Me), L-His(τ-Me), or D-His(τ-Me); A4 is Phe, D-Phe, Leu, D-Leu, Ile, D-Ile, Trp, D-Trp, Tyr, D-Tyr, Phg, bhPhe, Dpa, Bip, 1Nal, 2Nal, bhDpa, Amc, PheF5, hPhe, Igl, or cyclohexylalanine; A5 is Pro, D-Pro, Ser, D-Ser, Oic, bhPro, trans-4-PhPro, cis-4-PhPro, cis-5-PhPro, or Idc; A6 is Arg; A7 is Cys, D-Cys, Ser, D-Ser, Ala, D-Ala, Cys(S-tBut), homoCys, Pen, (D)Pen, S-tertiary butyl-cysteine, Cys(S-S-Pal), Cys(S-S-cysteamine-Pal), Cys(S-S-Cys-NHPal), or Cys(S-S-Cys); A8 is Arg; A9 is Phe, D-Phe, Leu, D-Leu, Ile, D-Ile, Tyr, D-Tyr, Trp, D-Trp, Phe-R^(a), D-Phe-R^(a), Dpa-R^(a), D-Dpa-R^(a), Trp-R^(a), bhPhe-R^(a), PheF5, N-MePhe, benzylamide, 2-aminoindane, bhPhe, Dpa, Bip, 1Nal, 2Nal, bhDpa, or cyclohexylalanine, which may or may not have R^(a) linked thereto, wherein R^(a) is palmitoyl-PEG- wherein PEG is PEG11 or miniPEG3, palmitoyl-PEG-PEG11, palmitoyl-PEG-miniPEG3, butanoyl (C4)-PEG11-, octanoyl (C8, Caprylic)-PEG11-, palmitoyl (C16)-PEG11-, or tetracosanoyl (C24, Lignoceric)-PEG11-; and A10 is Cys, D-Cys, Ser, D-Ser, Ala, D-Ala, Ida, Ahx-Ida(NHPal), or Ahx-Ida(NBzl2); wherein the carboxy-terminal amino acid is in amide or carboxy-form; wherein at least one sulfhydryl amino acid is present as one of the amino acids in the sequence; and wherein A1, A1 to A2, A10, or a combination thereof are optionally absent, and wherein bhAsp is 3-aminopentanedioic acid Ida is 2,2′-azanediyldiacetic acid; Ida(NHPal) is a palmitylamine amide on Ida side chain; Ida(NBzl2) is N,N′-Dibenzylamine amide on Ida side chain; N-MeAsp is methyl-L-aspartic acid; Ahx is aminohexanoic acid; Tle is L-tert-leucine; Inp is isonipecotic acid; Chg is L-α-cyclohexylglycine; bhThr is β-homothreonine; N-MeThr is (2S)-3-hydroxy-2-(methylamino)butanoic acid; His(π-Me) is N^(π)-methylhistidine; His(τ-Me) is N^(τ)-methylhistidine; Phg is L-phenylglycine; bhPhe is β-homophenylalanine; Dpa is 3,3-diphenyl-L-alanine; Bip is L-biphenylalanine; 1Nal is (1-naphthyl)-L-alanine; 2Nal is (2-naphthyl)-L-alanine; bhDpa is (S)-3-Amino-4,4-diphenylbutanoic acid; Amc is 4-(aminomethyl)cyclohexane carboxylic acid; PheF5 is (R)-2-amino-3-(perfluorophenyl)propanoic acid; hPhe is (S)-2-amino-4-phenylbutanoic acid; Igl is (S)-2-amino-2-(2,3-dihydro-1H-inden-2-yl)acetic acid; Oic is octahydroindole-2-carboxylic acid; bhPro is L-β-homoproline; trans-4-PhPro is (2S,4S)-4-phenylpyrrolidine-2-carboxylic acid; cis-4-PhPro is (2S,4R)-4-phenylpyrrolidine-2-carboxylic acid; cis-5-PhPro is (2R,5S)-5-phenylpyrrolidine-2-carboxylic acid; Idc is (R)-indoline-2-carboxylic acid; Cys(S-tBut) is S-t-Butylthio-L-cysteine; homoCys is L-homocysteine; Pen is L-Penicillamine; (D)Pen is D-Penicillamine; Cys(S-S-Pal) is palmitoyl attached to Cys via a disufide bond; Cys(S-S-cysteamine-Pal) is palmitoyl attached to Cys via SS-Cysteamine; Cys(S-S-Cys-NHPal) is palmitylamine attached to Cys via another Cys; Cys(S-S-Cys) is Cys attached to Cys via disulfide bond; N-MeArg is N^(ω)-methyl-L-arginine; PEG11 is O-(2-aminoethyl)-O′-(2-carboxyethyl)-undecaethyleneglycol; and miniPEG3 is 11-amino-3,6,9-trioxaundecanoic acid. 